Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
-
Publication Venue For
-
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium..
JCO2202459.
2023
-
Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes..
39:5004-5004.
2021
-
Evaluating a high-dimensional machine-learning model to predict hospital mortality among elderly cancer patients..
39:1512-1512.
2021
-
Impact of cancer on emergency department outcomes..
39:e18618-e18618.
2021
-
Impact of cancer on the risk of unplanned 30-day readmissions..
39:6581-6581.
2021
-
Impact of the VA opioid safety initiative on pain management for cancer patients..
39:102-102.
2021
-
Predictors of inpatient admission for pediatric cancer patients visiting the emergency department..
39:e22019-e22019.
2021
-
Impact of equal access healthcare on race disparities in bladder cancer..
39:399-399.
2021
-
Trends in short-term, long-term, and high-risk opioid use among older cancer patients..
38:187-187.
2020
-
RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)..
38:8020-8020.
2020
-
Determinants of secondary alterations in WWTR1-CAMTA1
fusion epithelioid hemangioendothelioma..
37:11045-11045.
2019
-
Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis..
37:7547-7547.
2019
-
Long-term risk of venous thromboembolism in survivors of childhood cancer: A report from the childhood cancer survivor study.
36:3141-3151.
2018
-
mRNA-nanoparticles to enhance and track dendritic cell migration..
36:72-72.
2018
-
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)..
35:2781-2789.
2017
-
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
35:2260-2267.
2017
-
Implementation of precision oncology in the Veterans Health Administration (VHA)..
35:6507-6507.
2017
-
Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus.
34:e73-e75.
2016
-
Use of targeted therapy in cancer patients in the end-of-life period..
32:129-129.
2014
-
ERRATA.
32:1387-1387.
2014
-
Randomized Noninferiority Trial of Telephone Versus In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer.
32:618-626.
2014
-
Quality of life among long-term survivors of non-Hodgkin lymphoma: a follow-up study..
31:272-279.
2013
-
Comparative Effectiveness Research: The Experience of the National Institute for Health and Clinical Excellence.
30:4267-4274.
2012
-
Copayment assistance and adherence to prescription medication among patients with cancer..
30:57-57.
2012
-
Development of a virtual multidisciplinary lung cancer tumor board in a community setting..
30:325-325.
2012
-
Examining potential cancer care disparities in an equal access system: Quality of colorectal cancer care (CRC) in the Veterans Affairs (VA) health care system.
30.
2012
-
Impact of race on early-stage lung cancer treatment and survival.
30.
2012
-
Persistence of quality improvement in a Veterans Affairs (VA) academic practice assessed by Quality Oncology Practice Initiative (QOPI).
30.
2012
-
Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery.
30.
2012
-
The evolution of supportive care quality measures portfolio and conformance.
30.
2012
-
Reply to P.K.L. Chin et al, P. Chambers et al, and J.H. Beumer et al.
30:3898-3899.
2012
-
Evaluation of a breast cancer survivorship clinic that uses a group medical appointment model: Patient program evaluation and financial analysis..
30:90-90.
2012
-
Reply to M.C. Chamberlain et al.
30:3316-3317.
2012
-
Reply to K.J. Van Zee et al.
30:3144-3145.
2012
-
Reply to K.A. Olaussen et al.
30:1568-1569.
2012
-
Reply to A. Goyal et al.
30:1019-1020.
2012
-
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy..
30.
2012
-
An analysis to quantify the overall survival (OS) benefit of sipuleucel-T accounting for the crossover in the control arm of the IMPACT study..
30:144-144.
2012
-
Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)..
30.
2012
-
Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy..
30:129-129.
2012
-
Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC)..
30:406-406.
2012
-
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)..
30:7-7.
2012
-
Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis..
30:480-480.
2012
-
Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer..
30:447-447.
2012
-
Post-traumatic stress symptoms in long-term non-Hodgkin's lymphoma survivors: does time heal?.
29:4526-4533.
2011
-
Reply to S. Hapani et al.
29:3490-3491.
2011
-
Reply to M.S. Lesniak.
29:3105-3106.
2011
-
Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina..
29:2683-2688.
2011
-
Reply to M.C. Chamberlain.
29.
2011
-
Reply to A. Gratwohl.
29.
2011
-
A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients..
29:e14026-e14026.
2011
-
A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED)..
29:2070-2070.
2011
-
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501)..
29:TPS223-TPS223.
2011
-
Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP)..
29:e15019-e15019.
2011
-
Allogeneic transplantation for patients with high-risk or refractory neuroblastoma..
29:9552-9552.
2011
-
Automated extraction of Quality Oncology Practice Initiative (QOPI) quality measures from the Veterans Health Administration (VHA) electronic health record system..
29:e16560-e16560.
2011
-
Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials..
29.
2011
-
Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM)..
29.
2011
-
Does enrollment setting influence patient attributes and outcomes in RTOG prostate cancer trials?.
29:4607-4607.
2011
-
Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC)..
29:4582-4582.
2011
-
Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer..
29:7004-7004.
2011
-
Impact of out-of-pocket expenses on cancer care.
29.
2011
-
Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales—A report from the Children's Oncology Group (COG)..
29:9515-9515.
2011
-
Pharmacodynamic and pharmacokinetic characterization of tumor proliferation during acute sunitinib (SU) withdrawal..
29:e13556-e13556.
2011
-
Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies..
29:e13503-e13503.
2011
-
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer..
29:3586-3586.
2011
-
Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma..
29.
2011
-
Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101..
29:4003-4003.
2011
-
Predictors of pulmonary toxicity in limited-stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high-dose (70 Gy) daily radiotherapy (RT): A pooled analysis of three CALGB studies..
29:7078-7078.
2011
-
Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer..
29:3082-3082.
2011
-
Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)..
29:10005-10005.
2011
-
Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma..
29:2082-2082.
2011
-
Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy..
29:524-524.
2011
-
Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma..
29:2055-2055.
2011
-
Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581.
29.
2011
-
Impact of out-of-pocket expenses on cancer care..
29:6006.
2011
-
Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)..
29:185-185.
2011
-
Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy..
29:118-118.
2011
-
Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)..
29:189-189.
2011
-
Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups..
29:126-126.
2011
-
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease..
29:198-198.
2011
-
A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC)..
29:281-281.
2011
-
Carcinoma of the ampulla of Vater: Patterns of failure after resection and benefit of adjuvant radiotherapy..
29:254-254.
2011
-
Multicenter evaluation of adjuvant therapy for gallbladder cancer..
29:251-251.
2011
-
Single-institution experience of preoperative chemoradiotherapy for locally advanced gastric cancer..
29:99-99.
2011
-
Reply to N. Lathia et al.
28.
2010
-
Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs..
28:4149-4153.
2010
-
Reply to F. Bellati et al.
28.
2010
-
A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401..
28:LBA4511-LBA4511.
2010
-
A single arm phase Ib study of RAD001 and sunitinib in patients with advanced renal cell carcinoma (RCC)..
28.
2010
-
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis..
28:8106-8106.
2010
-
A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.
28.
2010
-
A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma..
28:TPS306-TPS306.
2010
-
A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC).
28.
2010
-
Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV)..
28.
2010
-
Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM)..
28:2023-2023.
2010
-
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)..
28:7037-7037.
2010
-
CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma..
28:2089-2089.
2010
-
Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU)..
28:3094-3094.
2010
-
Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results..
28:7056-7056.
2010
-
Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI..
28:3050-3050.
2010
-
Correlation of the Oncotype DX recurrence score with a composite index comprised of ER, PR, HER2, and breast tumor grade..
28:10647-10647.
2010
-
Deep margin involvement after shave biopsy for melanoma and requirement for sentinel lymph node biopsy (SLNB)..
28:e19029-e19029.
2010
-
Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602..
28:8039-8039.
2010
-
Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results..
28:2060-2060.
2010
-
Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study..
28:TPS249-TPS249.
2010
-
Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer..
28:5027-5027.
2010
-
Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens..
28:10633-10633.
2010
-
Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM)..
28:2014-2014.
2010
-
Long-term survival from the initial trial of bevacizumab and irinotecan..
28.
2010
-
MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study..
28:9516-9516.
2010
-
Patient preferences for targeted agents in renal cell carcinoma (RCC): A benefit–risk conjoint study..
28:4596-4596.
2010
-
Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas..
28:2073-2073.
2010
-
Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG)..
28:2038-2038.
2010
-
Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC)..
28:e13527-e13527.
2010
-
Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results..
28:2055-2055.
2010
-
Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer..
28:TPS252-TPS252.
2010
-
Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC).
28.
2010
-
Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study.
28.
2010
-
Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial..
28:4637-4637.
2010
-
Use of gene expression signatures to identify origin of primary and therapeutic strategies for patients with advanced solid tumors..
28:10504-10504.
2010
-
Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A)..
28:e21009-e21009.
2010
-
Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
28.
2010
-
Utilization of genomic signatures for chemotherapy response in prospective clinical studies..
28:10513-10513.
2010
-
Reply to K. Shimada et al.
28.
2010
-
Reply to W. Wick et al.
28.
2010
-
American Society of Clinical Oncology guidance statement: the cost of cancer care..
27:3868-3874.
2009
-
Reply to C.D. Atkins.
27:2573.
2009
-
Reply to A. Katz et al.
27:2301-2302.
2009
-
To the editor.
27:829.
2009
-
In reply.
27:648-649.
2009
-
In reply.
26:5305.
2008
-
In reply.
26:5134.
2008
-
In reply.
26:4216-4217.
2008
-
In reply.
26:1906-1907.
2008
-
In reply.
26:3648-3649.
2008
-
Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life..
26:3331-3337.
2008
-
A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma.
26:10577-10577.
2008
-
A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo).
26:4605-4605.
2008
-
A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy.
26:8108-8108.
2008
-
A phase II trial of lapatinib in hormone refractory prostate cancer.
26.
2008
-
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603.
26.
2008
-
A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).
26:2010b-2010b.
2008
-
A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study.
26:10011-10011.
2008
-
Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations.
26:7027-7027.
2008
-
Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM).
26:2074-2074.
2008
-
Comparison of the biology of Down syndrome (DS) acute lymphoblastic leukemia (ALL) and non-DS ALL: Children’s Oncology Group (COG) study P9900.
26:10003-10003.
2008
-
Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.
26:2011-2011.
2008
-
Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients.
26:2026-2026.
2008
-
Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980.
26.
2008
-
Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM.
26.
2008
-
Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG).
26.
2008
-
Gene expression determinants of ovarian cancer platinum-response in older women.
26:22059-22059.
2008
-
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
26:9077-9077.
2008
-
Improving quality at university based hematology/oncology fellowship continuity clinic with the quality oncology practice initiative (QOPI).
26:6578-6578.
2008
-
Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients.
26:8057-8057.
2008
-
Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).
26:4063-4063.
2008
-
Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study.
26:8560-8560.
2008
-
LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402.
26:4109-4109.
2008
-
Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC).
26:15082-15082.
2008
-
Phase I trial of temozolomide plus O6
-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme.
26:2084-2084.
2008
-
Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC).
26:5173-5173.
2008
-
Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme.
26.
2008
-
Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma.
26.
2008
-
Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma.
26:4604-4604.
2008
-
Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM).
26:2062-2062.
2008
-
Predictors of survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
26:15522-15522.
2008
-
The actuarial incidence of brain metastases in 975 patients undergoing surgery for early-stage lung cancer.
26:8094-8094.
2008
-
The association between RT-induced changes in lung density and global lung function.
26:13543-13543.
2008
-
The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC).
26:4595-4595.
2008
-
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803.
26:4039-4039.
2008
-
The patient reported outcomes measurement information system—Cancer (PROMIS-Ca): Cancer-specific application of a generic fatigue measure.
26:6537-6537.
2008
-
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
26:5074-5074.
2008
-
Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea.
26:2071-2071.
2008
-
Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC).
26:15087-15087.
2008
-
Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas.
26:2021-2021.
2008
-
Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study.
26:6562-6562.
2008
-
Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies.
26:7511-7511.
2008
-
Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL).
26:14588-14588.
2008
-
ERRATUM.
26:1018-1018.
2008
-
In reply.
26:1013.
2008
-
In reply.
26:688-689.
2008
-
Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors..
26:934-941.
2008
-
In reply [12].
25:5674.
2007
-
In reply [2].
25:4851-4852.
2007
-
Concomitant chemoradiotherapy.
25:4031-4032.
2007
-
In reply [2].
25:2331.
2007
-
In reply [4].
25:2332.
2007
-
In reply [8].
25:1450-1451.
2007
-
In reply [14].
25:1149-1151.
2007
-
In Reply.
25:603-603.
2007
-
In reply [10].
25.
2007
-
Economics of new oncology drug development..
25:209-216.
2007
-
Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy..
24:3583-3589.
2006
-
In reply [8].
24:3313-3314.
2006
-
In reply [8].
24:2131-2132.
2006
-
In reply [2].
24:1480-1481.
2006
-
Decision making in pediatric oncology: who should take the lead? The decisional priority in pediatric oncology model..
24:160-165.
2006
-
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study..
23:9234-9242.
2005
-
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme..
23:9359-9368.
2005
-
Global role of the immune system in identifying cancer initiation and limiting disease progression..
23:8923-8925.
2005
-
In reply [10].
23:7752-7753.
2005
-
In reply [12].
23:2440-2441.
2005
-
In reply [4].
23:2107-2108.
2005
-
In reply [9].
23:7237-7238.
2005
-
Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations..
23:9319-9328.
2005
-
The changing face of prostate cancer..
23:8146-8151.
2005
-
Length of stay and mortality associated with febrile neutropenia among children with cancer..
23:7958-7966.
2005
-
Opportunities for targeted therapies in hepatocellular carcinoma..
23:8093-8108.
2005
-
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer..
23:7794-7803.
2005
-
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients..
23:8136-8139.
2005
-
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer..
23:7703-7720.
2005
-
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study..
23:7546-7554.
2005
-
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma..
23:7178-7187.
2005
-
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy..
23:6992-6998.
2005
-
Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation..
23:6481-6488.
2005
-
Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization, and health-related behaviors from the childhood cancer survivor study..
23:6499-6507.
2005
-
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure..
23:6556-6560.
2005
-
Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study..
23:6508-6515.
2005
-
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer..
23:6117-6125.
2005
-
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma..
23:5511-5519.
2005
-
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study..
23:5705-5717.
2005
-
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas..
23:5305-5313.
2005
-
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome..
23:5099-5107.
2005
-
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer..
23:4888-4896.
2005
-
Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers..
23:4713-4718.
2005
-
Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database..
23:4735-4741.
2005
-
Locally advanced pancreatic cancer..
23:4538-4544.
2005
-
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma..
23:4390-4398.
2005
-
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials..
23:4198-4214.
2005
-
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia..
23:4110-4116.
2005
-
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer..
23:3706-3712.
2005
-
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732..
23:3752-3759.
2005
-
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer..
23:3668-3675.
2005
-
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer..
23:3502-3508.
2005
-
Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point..
23:3475-3479.
2005
-
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies..
23:3396-3403.
2005
-
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group..
23:3376-3382.
2005
-
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma..
23:3279-3287.
2005
-
Functional imaging in lung cancer..
23:3203-3211.
2005
-
Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy..
23:3138-3140.
2005
-
Randomized trial of hyperthermia and radiation for superficial tumors..
23:3079-3085.
2005
-
Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results..
23:2864-2865.
2005
-
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18..
23:2831-2839.
2005
-
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies..
23:2502-2512.
2005
-
Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer..
23:2434-2435.
2005
-
Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001..
23:2201-2207.
2005
-
Merkel cell carcinoma: prognosis and treatment of patients from a single institution..
23:2300-2309.
2005
-
Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus..
23:2325-2331.
2005
-
Role of transforming growth factor Beta in human cancer..
23:2078-2093.
2005
-
Erratum.
23:1337-1337.
2005
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer..
23:792-799.
2005
-
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study..
23:482-493.
2005
-
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001)..
23:525-531.
2005
-
In reply [2].
23:8537-8538.
2005
-
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)..
23:190-196.
2005
-
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline..
22:4979-4990.
2004
-
Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer..
22:4907-4917.
2004
-
Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer..
22:4795-4803.
2004
-
Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer..
22:4795-4803.
2004
-
White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor..
22:4551-4560.
2004
-
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium..
22:4329-4340.
2004
-
Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy..
22:4432-4434.
2004
-
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621..
22:4290-4301.
2004
-
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study..
22:4302-4311.
2004
-
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions..
22:4059-4066.
2004
-
Matched-pair analysis of survival of never smokers and ever smokers with squamous cell carcinoma of the head and neck..
22:3981-3988.
2004
-
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV..
22:3466-3474.
2004
-
Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study..
22:3558-3562.
2004
-
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130..
22:3277-3283.
2004
-
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor..
22:3357-3365.
2004
-
Managing accrual in cooperative group clinical trials..
22:2997-3002.
2004
-
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial..
22:2610-2616.
2004
-
New drug delivery approach for the treatment of prostate cancer (preclinical results and phase I study results)..
22:4661.
2004
-
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study..
22:2321-2327.
2004
-
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma..
22:2452-2460.
2004
-
Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations..
22:2202-2206.
2004
-
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma..
22:2078-2083.
2004
-
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients..
22:1823-1829.
2004
-
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis..
22:1785-1796.
2004
-
How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?.
22:1532-1533.
2004
-
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)..
22:1025-1033.
2004
-
Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma..
22:984-993.
2004
-
Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study..
22:999-1006.
2004
-
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461..
22:1087-1094.
2004
-
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114..
22:648-657.
2004
-
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group..
22:537-556.
2004
-
In Reply:.
22:572-573.
2004
-
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy..
22:439-445.
2004
-
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19..
22:269-276.
2004
-
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study..
22:166-174.
2004
-
In reply.
22:2756.
2004
-
Phase II trial of gefitinib in recurrent glioblastoma..
22:133-142.
2004
-
In Reply:.
21:4659-4660.
2003
-
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices..
21:4524-4531.
2003
-
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era..
21:4001-4008.
2003
-
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study..
21:3814-3825.
2003
-
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114..
21:3623-3628.
2003
-
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133..
21:3512-3519.
2003
-
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma..
21:3402-3408.
2003
-
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm..
21:2889-2895.
2003
-
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663..
21:2673-2678.
2003
-
Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study..
21:2754-2759.
2003
-
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication..
21:2589-2596.
2003
-
Barriers to clinical trial participation by older women with breast cancer..
21:2268-2275.
2003
-
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era..
21:2163-2172.
2003
-
High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas..
21:2187-2191.
2003
-
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group..
21:1937-1943.
2003
-
Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study..
21:1359-1365.
2003
-
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma..
21:1301-1306.
2003
-
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer..
21:1232-1237.
2003
-
To the editor [3].
21:1192.
2003
-
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care..
21:855-863.
2003
-
Phase II trial of temozolomide in patients with progressive low-grade glioma..
21:646-651.
2003
-
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583..
21:490-495.
2003
-
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma..
21:514-519.
2003
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer..
21:60-65.
2003
-
Update on late relapse of germ cell tumor: a clinical and molecular analysis..
21:113-122.
2003
-
Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables..
20:4344-4352.
2002
-
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431..
20:4191-4198.
2002
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin..
20:3804-3814.
2002
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors..
20:3792-3803.
2002
-
Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial..
20:3785-3791.
2002
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480..
20:3369-3375.
2002
-
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition..
20:3328-3343.
2002
-
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide - Reply.
20:3181-3182.
2002
-
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide..
20:3180-3181.
2002
-
Treatment of newly diagnosed glioblastoma multiforme..
20:3179-3180.
2002
-
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma..
20:2995-3000.
2002
-
Phase II study of carboplatin in children with progressive low-grade gliomas..
20:2951-2958.
2002
-
Quality of life after prostate cancer treatment..
20:3038.
2002
-
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes..
20:2701-2712.
2002
-
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study..
20:2441-2452.
2002
-
Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome..
20:2537-2544.
2002
-
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B..
20:2429-2440.
2002
-
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma..
20:2277-2283.
2002
-
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114..
20:1744-1750.
2002
-
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy..
20:1405-1410.
2002
-
Phase II Trial of Murine 131
I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas.
20:1389-1397.
2002
-
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas..
20:1389-1397.
2002
-
Radiation dose escalation in combined-modality therapy for esophageal cancer..
20:1151-1153.
2002
-
Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer..
20:1036-1042.
2002
-
Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer..
20:987-993.
2002
-
Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology..
20:770-775.
2002
-
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia..
20:674-679.
2002
-
Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation..
19:3758-3765.
2001
-
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system..
19:3622-3634.
2001
-
Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design..
19:3445-3446.
2001
-
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer..
19:3025-3028.
2001
-
Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study..
19:2696-2704.
2001
-
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy..
19:2381-2389.
2001
-
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B..
19:2509-2516.
2001
-
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy..
19:1698-1706.
2001
-
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia..
19:1589-1599.
2001
-
Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy..
19:1583-1585.
2001
-
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer..
19:1233-1234.
2001
-
73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer..
19:705-711.
2001
-
Application of a new multinomial phase II stopping rule using response and early progression..
19:785-791.
2001
-
Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction?.
19:543-550.
2001
-
Melastatin expression and prognosis in cutaneous malignant melanoma..
19:568-576.
2001
-
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma..
19:376-388.
2001
-
Impact of number of nodes retrieved on outcome in patients with rectal cancer..
19:157-163.
2001
-
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer..
19:44-53.
2001
-
Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer..
18:3883-3893.
2000
-
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas..
18:3862-3872.
2000
-
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel..
18:3558-3585.
2000
-
Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer..
18:3529-3534.
2000
-
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma..
18:3522-3528.
2000
-
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer..
18:3339-3345.
2000
-
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation..
18:3004-3011.
2000
-
Angiogenesis in neuroblastoma..
18:2789-2791.
2000
-
Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy..
18:2522-2528.
2000
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group..
18:2354-2362.
2000
-
Two patients with sarcoma. Case 2. Uterine sarcoma..
18:2343-2344.
2000
-
Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma..
18:2040-2045.
2000
-
What threshold for adjuvant therapy in older breast cancer patients?.
18:1709-1717.
2000
-
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies..
18:995-1003.
2000
-
Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy..
18:1110-1115.
2000
-
Acute respiratory failure secondary to lymphangitic carcinomatosis (vol 18, pg 229, 2000).
18:944-944.
2000
-
Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study..
18:455-462.
2000
-
Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status..
18:600-608.
2000
-
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents..
18:860-867.
2000
-
Case 2: acute respiratory failure secondary to lymphangitic carcinomatosis..
18:229-232.
2000
-
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia..
18:348-357.
2000
-
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered..
17:3767-3775.
1999
-
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group..
17:3461-3467.
1999
-
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support..
17:3064-3074.
1999
-
Telomerase activity and prognosis in primary breast cancers..
17:3075-3081.
1999
-
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group..
17:2762-2771.
1999
-
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420..
17:2831-2839.
1999
-
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer..
17:2710-2720.
1999
-
Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma..
17:2403-2411.
1999
-
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study..
17:2506-2513.
1999
-
Irinotecan therapy in adults with recurrent or progressive malignant glioma..
17:1516-1525.
1999
-
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2..
17:1040-1046.
1999
-
Phase II trial of N,N-diethyl,2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study.
17:3431-3437.
1999
-
Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group..
17:4-11.
1999
-
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma..
16:3851-3857.
1998
-
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma..
16:3843-3850.
1998
-
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response..
16:3607-3615.
1998
-
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer..
16:3528-3536.
1998
-
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma..
16:3570-3575.
1998
-
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03..
16:3576-3583.
1998
-
Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain..
16:3230-3237.
1998
-
Tumor-suppressor p53: implications for tumor development and prognosis..
16:3158-3168.
1998
-
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers..
16:2739-2744.
1998
-
Programs for adult survivors of childhood cancer..
16:2864-2867.
1998
-
Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications..
16:2468-2477.
1998
-
Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey..
16:2542-2547.
1998
-
Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083..
16:2466-2467.
1998
-
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results..
16:2202-2212.
1998
-
Unknown primary tumors metastatic to liver..
16:2105-2112.
1998
-
Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer..
16:1689-1696.
1998
-
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia..
16:1885-1889.
1998
-
Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study..
16:1723-1728.
1998
-
Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B..
16:1954-1960.
1998
-
Comorbidity and functional status are independent in older cancer patients..
16:1582-1587.
1998
-
Prospective investigation of positron emission tomography in lung nodules..
16:1075-1084.
1998
-
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant..
16:1008-1012.
1998
-
Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want?.
16:133-138.
1998
-
Pancreatic panniculitis..
15:3418-3419.
1997
-
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study..
15:3378-3387.
1997
-
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma..
15:2905-2909.
1997
-
Are there sex biases in standardized tests of radiation oncology knowledge?.
15:2722-2727.
1997
-
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors..
15:1814-1823.
1997
-
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?.
15:2056-2066.
1997
-
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas..
15:928-937.
1997
-
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461..
15:466-475.
1997
-
Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer..
15:735-743.
1997
-
Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations..
15:230-238.
1997
-
Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies..
15:18-25.
1997
-
Race and myeloma survival..
14:3175.
1996
-
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer..
14:2774-2784.
1996
-
Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer..
14:2322-2330.
1996
-
Response of recurrent medulloblastoma to low-dose oral etoposide..
14:1922-1927.
1996
-
Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology..
14:1957-1960.
1996
-
Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: Preliminary results of an ongoing phase I trial..
14:2022-2022.
1996
-
Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life..
14:1565-1572.
1996
-
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil..
14:1192-1200.
1996
-
Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment..
14:1093-1097.
1996
-
Reducing patient eligibility criteria in cancer clinical trials..
14:1364-1370.
1996
-
Chemotherapy in malignant pleural mesothelioma. A review..
14:1007-1017.
1996
-
Predicting the risk of bacteremia in childen with fever and neutropenia..
14:919-924.
1996
-
High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study..
14:382-388.
1996
-
Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma..
14:405-414.
1996
-
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors..
14:220-226.
1996
-
Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival.
14:1913-1921.
1996
-
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study..
14:135-141.
1996
-
Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia..
13:2973-2979.
1995
-
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma..
13:2776-2783.
1995
-
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials..
13:2457-2463.
1995
-
Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy..
13:2238-2246.
1995
-
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin..
13:2094-2103.
1995
-
Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx..
13:2077-2083.
1995
-
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B..
13:1871-1879.
1995
-
Stereotactic radiosurgery for recurrent malignant gliomas..
13:1642-1648.
1995
-
Placebo-controlled randomized study of hydrazine sulfate in lung cancer..
13:1529-1530.
1995
-
Tumor proliferation in rectal cancer following preoperative irradiation..
13:1417-1424.
1995
-
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial..
13:1231-1237.
1995
-
Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung..
13:1265-1279.
1995
-
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy..
13:596-602.
1995
-
Pain and depression in patients with newly diagnosed pancreas cancer..
13:748-755.
1995
-
Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis..
13:464-469.
1995
-
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma..
12:2552-2558.
1994
-
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma..
12:2559-2566.
1994
-
Anticancer antibodies for lung cancer..
12:2519-2520.
1994
-
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma..
12:2296-2300.
1994
-
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study..
12:1436-1442.
1994
-
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B..
12:1113-1120.
1994
-
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients..
12:1272-1280.
1994
-
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma..
12:946-953.
1994
-
Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support..
12:1005-1011.
1994
-
Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation..
12:679-682.
1994
-
Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease..
12:306-311.
1994
-
Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience..
11:2342-2350.
1993
-
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B..
11:2081-2089.
1993
-
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma..
11:2173-2180.
1993
-
Ten years' experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma..
11:2054-2055.
1993
-
OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures..
11:1506-1510.
1993
-
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B..
11:1559-1565.
1993
-
Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission..
11:1353-1360.
1993
-
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group..
11:1223-1229.
1993
-
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy..
11:1329-1335.
1993
-
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer..
11:1132-1143.
1993
-
Postoperative radiation therapy for high-risk colon carcinoma..
11:1112-1117.
1993
-
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer..
11:425-433.
1993
-
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer..
11:330-335.
1993
-
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma..
11:77-83.
1993
-
Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents..
11:84-90.
1993
-
Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia..
10:1723-1729.
1992
-
Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery..
10:1553-1560.
1992
-
Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma..
10:1574-1578.
1992
-
Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score..
10:1390-1396.
1992
-
Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin..
10:1278-1283.
1992
-
Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study..
10:1237-1244.
1992
-
Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen..
10:1057-1065.
1992
-
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies..
10:1001-1006.
1992
-
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer..
10:747-752.
1992
-
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer..
10:541-548.
1992
-
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck..
10:257-263.
1992
-
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group..
10:282-291.
1992
-
Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study..
10:249-256.
1992
-
Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity..
9:2110-2119.
1991
-
Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia..
9:1570-1574.
1991
-
Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease..
9:1575-1579.
1991
-
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X..
9:1341-1347.
1991
-
Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy: a Pediatric Oncology Group study..
9:1189-1195.
1991
-
Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma..
9:843-849.
1991
-
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine..
9:491-498.
1991
-
The pattern of intrathoracic Hodgkin's disease assessed by computed tomography..
9:438-443.
1991
-
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial..
9:85-93.
1991
-
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma..
8:2027-2031.
1990
-
Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy..
8:1352-1361.
1990
-
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction..
8:1231-1238.
1990
-
Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle..
8:638-647.
1990
-
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy..
8:491-501.
1990
-
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer..
8:313-318.
1990
-
Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma..
7:1288-1294.
1989
-
Flow cytometry as a predictive indicator in patients with operable gastric cancer..
7:1105-1112.
1989
-
Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma..
7:1003-1008.
1989
-
Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma..
7:904-911.
1989
-
Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium..
7:439-444.
1989
-
Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas..
6:1703-1707.
1988
-
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer..
6:1368-1376.
1988
-
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study..
6:839-853.
1988
-
Ovarian function following marrow transplantation for aplastic anemia or leukemia..
6:813-818.
1988
-
Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment..
6:819-824.
1988
-
High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia..
6:576-582.
1988
-
Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer..
6:451-456.
1988
-
Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development..
6:308-314.
1988
-
Rational for "eight-in-one" chemotherapy..
6:393-395.
1988
-
Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis--a Pediatric Oncology Group Study..
6:34-43.
1988
-
Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study..
6:26-33.
1988
-
Effects of socioeconomic and clinical factors on survival in multiple myeloma..
5:1977-1984.
1987
-
Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin..
5:1900-1911.
1987
-
Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia..
5:1613-1620.
1987
-
Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation..
5:1340-1347.
1987
-
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease..
5:731-734.
1987
-
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms..
5:464-471.
1987
-
Retroperitoneal fibrosis following treatment for Hodgkin's disease..
5:231-232.
1987
-
Malignant melanoma in the elderly..
5:100-106.
1987
-
A comparison of randomized concurrent control groups with matched historical control groups: are historical controls valid?.
4:1114-1120.
1986
-
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment..
4:888-899.
1986
-
Gastrointestinal involvement and multiple lymphomatous polyposis in mantle-zone lymphoma..
4:866-873.
1986
-
Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: a Pediatric Oncology Group study..
4:170-177.
1986
-
Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease..
3:1490-1494.
1985
-
The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia..
3:776-781.
1985
-
Obstructive and perforative colonic carcinoma: patterns of failure..
3:379-384.
1985
-
Changes in criteria for tumor response..
3:287.
1985
-
Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report..
2:1200-1208.
1984
-
Sudden death in cancer patients receiving lithium..
2:1270-1276.
1984
-
Nutritional parameters affecting erythrocyte polyamine levels in cancer patients..
2:1157-1164.
1984
-
An approach to conducting epidemiologic research within cooperative clinical trials groups..
2:670-675.
1984
-
Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil..
1:663-664.
1983
-
Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapy..
1:471-476.
1983
-
Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols.
1:462-470.
1983
-
Reply to D.J. Gallagher et al.
27.
2009
-
In reply [2].
23:1322-1323.
2005
-
Frequency of Practice-Changing Findings Identified by Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies
2022
-
An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.
2022
-
Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.
2022
-
Atezolizumab (atezo) with or without Bacille Calmette-Guérin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study.
2022
-
Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
2022
-
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.
2022
-
Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE).
2022
-
Exposure-adjusted safety analyses of the VISION phase 3 trial of 177
Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
2022
-
Factors associated with gene mutation testing in United States veterans with metastatic castration-resistant prostate cancer.
2022
-
Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.
2022
-
HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).
2022
-
Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.
2022
-
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).
2022
-
Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).
2022
-
Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo
mHSPC (M1 at diagnosis): Post hoc
analysis of the phase 3 ARCHES trial.
2022
-
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
2022
-
PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2022
-
Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).
2022
-
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.
2022
-
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
2022
-
Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).
2022
-
Veterans affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligorecurrent prostate cancer (VA STARPORT).
2022
-
A phase 1b study of sotorasib, a specific and irreversible KRASG12C
inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).
2022
-
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
2022
-
MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress.
2022
-
Metastatic bulk to predict subclonal heterogeneity by ctDNA in RAS/RAF-wildtype colorectal cancer.
2022
-
Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2022
-
Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.
2022
-
Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).
2022
-
REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.
2022
-
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.
2022
-
Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA
mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2022
-
A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma
2022
-
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2022
-
A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).
2022
-
A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
2022
-
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatmentnaive metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186-Trials in progress
2022
-
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).
2022
-
Age-associated differences in transcriptional expression and tumor immune microenvironment composition among older patients with cancer
2022
-
Assessing feasibility and utility of an implicit bias training program for addressing disparities in cancer clinical trial participation.
2022
-
Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer immunotherapy studies.
2022
-
Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).
2022
-
Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).
2022
-
Association of Medicaid expansion under the Affordable Care Act and overall survival among children with cancer.
2022
-
Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC).
2022
-
Attribution of symptoms to adjuvant endocrine therapy and association with adherence among older women with breast cancer: A qualitative study.
2022
-
Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas (HGGs)
2022
-
Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).
2022
-
Body composition in patients with metastatic renal cell carcinoma receiving ipilimumab plus nivolumab.
2022
-
Cancer doesn't know what day of the week it is: Temporal trends in day of death, 2000-2017.
2022
-
Changes in cancer mortality rates after Medicaid expansion under the Affordable Care Act and the role of changes in stage at diagnosis.
2022
-
Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.
2022
-
Clinical markers of successful liquid biopsy-based genomic profiling in veterans with prostate cancer.
2022
-
Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and >= 75 years: ARCHES post hoc analysis.
2022
-
Clinical outcomes of immune checkpoint inhibitor (ICI) therapy among Veterans Affairs patients with colorectal cancer and discordant dMMR/MSI-H status.
2022
-
Cobimetinib plus vemurafenib (C plus V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study
2022
-
Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma.
2022
-
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
2022
-
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors
2022
-
Development of a predictive model for emergency room utilization and unanticipated hospital admission in patients receiving cancer treatment for solid tumor malignancies.
2022
-
Differences in patient and caregiving partner responses to individual items on the FACIT-COST questionnaire.
2022
-
Discordance between patient with cancer and caregiving partner self-reported financial toxicity.
2022
-
Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).
2022
-
Efficacy of a brief telemedicine-based cognitive behavioral treatment (BRIGHT) versus attention control for head and neck cancer survivors with body image distress: A randomized trial
2022
-
FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, global, multinational study.
2022
-
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).
2022
-
Frequency and outcomes of molecularly guided off-label targeted agent prescriptions in the VA National Precision Oncology Program (NPOP).
2022
-
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls.
2022
-
GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
2022
-
Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).
2022
-
Human papillomavirus (HPV) vaccine hesitancy trends in the United States.
2022
-
Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.
2022
-
Identifying disparities in gynecologic cancer: Results and analysis from a patient preference survey.
2022
-
Impact of high-deductible health plans on delays in metastatic cancer diagnosis.
2022
-
Incorporating patient-reported outcome data into a hematopoietic cell transplant survival calculator.
2022
-
Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
2022
-
Molecular profiling of dedicated lung cancer biopsy tissue sample collected at time of diagnostic bronchoscopy.
2022
-
NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).
2022
-
Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1
2022
-
Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.
2022
-
Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC).
2022
-
Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)
2022
-
Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.
2022
-
Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
2022
-
Predictors of differential outcomes according to response to induction chemotherapy in high-risk neuroblastoma.
2022
-
Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
2022
-
Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.
2022
-
Racial differences in genomic profiling of prostate cancer at the durham veterans affairs medical center.
2022
-
Racial disparity in receipt of immunotherapy treatment among elderly patients with head and neck cancer.
2022
-
Racial/ethnic disparities in serious illness communication for patients with cancer.
2022
-
Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.
2022
-
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
2022
-
Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.
2022
-
State public welfare spending and racial/ethnic disparities in overall survival among adults with cancer.
2022
-
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.
2022
-
Surgical window-of-opportunity study of megestrol acetate compared with megestrol acetate and metformin for endometrial intraepithelial neoplasia
2022
-
Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
2022
-
The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
2022
-
The relationship between patient-reported distress and healthcare utilization in mNSCLC.
2022
-
Tolerability of [Lu-177]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.
2022
-
Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.
2022
-
Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).
2022
-
Variation in patient demographics across different modalities of tele-oncology
2022
-
Veterans affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligorecurrent prostate cancer (VA STARPORT)
2022
-
[Ga-68]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [Lu-177]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
2022
-
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.
2022
-
Evolving role of an oncology telehealth nurse at an NCI-designated cancer institute.
2021
-
Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer (PaRTNer): Baseline financial toxicity and attitudes toward costs from a pilot study.
2021
-
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
2021
-
Sociodemographic differences in patient-reported pain and pain management of head and neck cancer patients in a community oncology setting.
2021
-
A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML).
2021
-
A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.
2021
-
A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).
2021
-
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
2021
-
A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
2021
-
AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
2021
-
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.
2021
-
Advance care planning billing practices and documentation quality for cancer patients requiring hospitalization.
2021
-
An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).
2021
-
Assessing the use of low value oncology care following the release of Choosing Wisely guidelines.
2021
-
Assessment of HER2 (ERBB2
) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).
2021
-
Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).
2021
-
Associations of coping strategies with quality of life (QOL) and mood in patients with acute myeloid leukemia (AML).
2021
-
Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.
2021
-
Cancer specialists in the VA as early adopters of clinical genetic services.
2021
-
Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
2021
-
Code status transitions in patients with high-risk acute myeloid leukemia (AML).
2021
-
Comprehensive genomic profiling in advanced/metastatic colorectal cancer: Number needed to test and budget impact of expanded first-line use.
2021
-
Depression, chronic pain, and high-impact chronic pain among cancer survivors.
2021
-
Detection of actionable molecular alterations through combined DNA/RNA molecular profiling of biopsies collected in early-stage lung cancer at time of diagnosis.
2021
-
Disparities in cardiovascular risk factors by race/ethnicity among adult survivors of childhood cancer: A report from the Childhood Cancer Survivorship Study (CCSS).
2021
-
Disparities in surveillance imaging after breast conserving surgery for primary DCIS.
2021
-
Distress in a pandemic: The association of the coronavirus disease-2019 (COVID-19) pandemic with distress and quality of life in hematopoietic stem cell transplantation (HSCT).
2021
-
Effect of type and timing of systemic therapy on risk of radiation necrosis in patients with HER2+ breast cancer brain metastases.
2021
-
Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
2021
-
Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).
2021
-
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.
2021
-
FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.
2021
-
FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study.
2021
-
First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).
2021
-
GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
2021
-
Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.
2021
-
Identification of pathogenic CDK12
alterations in cell-free DNA (cfDNA) from patients with breast cancer.
2021
-
Impact of BRAF mutations on outcomes in metastatic melanoma with central nervous system metastases treated with immune checkpoint inhibitors.
2021
-
Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).
2021
-
Impact of machine learning-directed on-treatment evaluations on cost of acute care visits: Economic analysis of SHIELD-RT.
2021
-
Inflammatory myofibroblastic tumor: A multi-institutional study from the pediatric surgical oncology research collaborative.
2021
-
Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.
2021
-
Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.
2021
-
KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
2021
-
LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.
2021
-
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
2021
-
Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.
2021
-
Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma.
2021
-
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
2021
-
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).
2021
-
Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.
2021
-
P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).
2021
-
PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
2021
-
Palliative care and coping in patients with acute myeloid leukemia receiving intensive induction therapy: A mediation analysis of data from a randomized trial.
2021
-
Patient concerns and disruptions in cancer care during the COVID-19 pandemic.
2021
-
Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.
2021
-
Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.
2021
-
Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
2021
-
Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).
2021
-
Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.
2021
-
Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).
2021
-
Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.
2021
-
Real-world outcomes among prostate cancer patients with BRCA2
gene variants compared to variants in other homologous DNA repair genes.
2021
-
Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation.
2021
-
Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma.
2021
-
Risk and distribution of venous thromboembolic events during treatment for advanced endometrial cancer.
2021
-
Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model.
2021
-
Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).
2021
-
Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).
2021
-
Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.
2021
-
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
2021
-
Suicide risk following a new cancer diagnosis among veterans in Veterans Health Administration care.
2021
-
Survival among patients with untreated metastatic breast cancer.
2021
-
TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.
2021
-
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.
2021
-
The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
2021
-
The mutational landscape of older patients with IDH wild-type glioblastoma (GBM).
2021
-
The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).
2021
-
Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C
inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
2021
-
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
2021
-
ASSET: Alternative schedule sunitinib in metastatic renal cell carcinoma (RCC)—Cardiopulmonary exercise testing (CPET).
2021
-
Angiogenic and T-effector subgroups identified by gene expression profiling (GEP) and propensity for PBRM1 and BAP1 alterations in clear cell renal cell carcinoma (ccRCC).
2021
-
CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.
2021
-
Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
2021
-
EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
2021
-
Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.
2021
-
Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).
2021
-
Hyperthermia, bladder pressure, and intravesical drug delivery.
2021
-
Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).
2021
-
Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.
2021
-
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
2021
-
Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
2021
-
Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).
2021
-
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
2021
-
PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).
2021
-
Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.
2021
-
Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
2021
-
Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).
2021
-
Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.
2021
-
Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.
2021
-
Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).
2021
-
Single-arm phase II study of low-dose paclitaxel and pembrolizumab in platinum-refractory metastatic urothelial carcinoma (UC).
2021
-
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.
2021
-
Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).
2021
-
Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.
2021
-
KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma.
2021
-
MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.
2021
-
MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
2021
-
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS
wild-type metastatic colorectal cancer (mCRC).
2021
-
Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).
2021
-
Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).
2021
-
Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling.
2021
-
Risk factors for gastric cancers in the United States: Variation by anatomic site and race/ethnicity.
2021
-
Clonal hematopoiesis association with cardiac function and mortality in patients with solid tumors.
2021
-
Predictors of inpatient admission for pediatric cancer patients visiting the emergency department.
2021
-
Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system.
2021
-
ERBB2 amplifications and mutations in 109 advanced breast cancer patients by next-generation sequencing
2020
-
Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).
2020
-
A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)
2020
-
A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415
2020
-
A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab
2020
-
ADRB2 expression in progressive metastatic castration-resistant prostate cancer
2020
-
AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY
2020
-
Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
2020
-
Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials
2020
-
Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide
2020
-
Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC)
2020
-
Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC)
2020
-
Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).
2020
-
Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab
2020
-
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
2020
-
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143)
2020
-
Patient-reported outcomes on treatment-related side effects in renal cell carcinoma
2020
-
Provider referral patterns following nephrectomy in high-risk locoregional renal cell carcinoma
2020
-
Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC)
2020
-
Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors
2020
-
A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukemia choose different treatment paths.
2020
-
A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA
2020
-
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
2020
-
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
2020
-
A randomized controlled trial (RCT) testing a mobile application (app) to identify cancer treatment-related financial assistance.
2020
-
A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).
2020
-
AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).
2020
-
Adult lymphoma-associated hemophagocytic lymphohistiocytosis: A clinical case series in a predominantly Hispanic cohort from the University of Miami/Jackson Memorial Hospital.
2020
-
Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.
2020
-
ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).
2020
-
Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.
2020
-
Associations of care experiences with survival among people with cancer in SEER-CAHPS, 2006 to 2017.
2020
-
BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.
2020
-
Can a brief multimedia intervention facilitate breast cancer patients' communication about sexual health? Findings from a randomized controlled trial.
2020
-
Changes in cancer mortality rates after the adoption of the Affordable Care Act.
2020
-
Circulating stromal cells as a potential blood-based biomarker for screening invasive solid tumors.
2020
-
Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
2020
-
Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).
2020
-
Cobimetinib plus vemurafenib (C plus V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study
2020
-
CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS(G12C), in patients with advanced colorectal cancer.
2020
-
Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
2020
-
Comparative effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: A parametric survival network meta-analysis of randomized controlled trials.
2020
-
Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.
2020
-
Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.
2020
-
DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.
2020
-
DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival
2020
-
Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.
2020
-
Enrollment barriers of adolescents and young adults (AYA) on the non-chemotherapy arm of ARST1321.
2020
-
Exploring multiple myeloma survivor interest in lifestyle interventions.
2020
-
Fatigue trajectories in long-term non-Hodgkin lymphoma survivors.
2020
-
GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
2020
-
Genetic counseling referrals after next generation sequencing testing.
2020
-
Genome-wide methylation analysis in long-term survivors of glioblastoma (GBM).
2020
-
Healthcare resource utilization and total cost of care in older patients with acute myeloid leukemia ineligible for intensive chemotherapy.
2020
-
INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.
2020
-
Identification of pathogenic ROSI alterations in cell-free DNA (cfDNA) from patients with breast cancer.
2020
-
Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.
2020
-
Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).
2020
-
Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery.
2020
-
KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
2020
-
Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.
2020
-
MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.
2020
-
Missing data in breast cancer: Relationship with survival in national databases.
2020
-
Molecular features of gliomas with high tumor mutational burden.
2020
-
Multi-institutional comparative effectiveness of advanced cancer longitudinal imaging response evaluation methods: Current practice versus artificial intelligence-assisted.
2020
-
Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies.
2020
-
Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML).
2020
-
NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer.
2020
-
Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2020
-
Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2020
-
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
2020
-
Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship.
2020
-
Ovarian cancer clinical trials: Study the studies to terminate the terminations.
2020
-
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
2020
-
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
2020
-
Patient and physician decision-making on the use of novel agents in chronic lymphocytic leukemia (CLL): What drives preferences?
2020
-
Patient preferences and expectations of systemic therapy in renal cell carcinoma.
2020
-
Patient-reported distress and healthcare utilization in patients with advanced cancer.
2020
-
Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.
2020
-
Patterns of inpatient palliative care consultation for patients with brain and spine metastases.
2020
-
Pertuzumab plus trastuzumab (P plus T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study
2020
-
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
2020
-
Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).
2020
-
Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.
2020
-
Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.
2020
-
Potency of CD8+T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model
2020
-
Practice gaps and challenges integrating new immuno-oncology agents in the treatment of cancer patients in the United States: A mixed-method study.
2020
-
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
2020
-
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
2020
-
Radiotherapy use in the treatment of gastrointestinal cancers in Medicare patients: An analysis of a CMS database
2020
-
Real-world examination of remission patterns in patients (pts) with acute myeloid leukemia (AML).
2020
-
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: Are some patients missing out?
2020
-
Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.
2020
-
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
2020
-
Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
2020
-
Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
2020
-
Segmental chromosome aberrations and clinical response impact outcome of inss stage Ill patients >= 18 months with unfavorable histology and without MYCN amplification: A Children's Oncology Group (COG) report.
2020
-
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
2020
-
Shared decision-making attitudes and practices in multidisciplinary cancer care teams.
2020
-
Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.
2020
-
Stem cell transplant and financial toxicity: A single-center prospective cohort analysis.
2020
-
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
2020
-
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
2020
-
The effect of body mass index (BMI) on survival in patients with breast cancer and obesity-associated conditions.
2020
-
The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).
2020
-
The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board.
2020
-
Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.
2020
-
Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
2020
-
Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis.
2020
-
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.
2020
-
Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
2020
-
A prototype mobile application to improve communication about symptom management.
2019
-
Acute care and hydration due to chemotherapy-induced nausea and vomiting (CINV) among patients receiving NEPA prophylaxis for anthracycline + cyclophosphamide (AC).
2019
-
Billed palliative care services and end-of-life care in patients with hematologic malignancies.
2019
-
Digital Supportive Care Awareness and Navigation (D-SCAN): Results of a pilot randomized trial.
2019
-
Integration of electronic patient-reported outcomes into clinical workflows within the Epic electronic medical record.
2019
-
Living with multiple myeloma: A life disrupted.
2019
-
Oral adherence in adults with acute myeloid leukemia (AML): Results of a mixed methods study.
2019
-
Real-world experience with electronic patient reported outcomes and missing items: "Don't ask me irrelevant questions".
2019
-
An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.
2019
-
Experiences of pediatric lymphoma patients undergoing treatment in Malawi across all PROMIS-25 domains.
2019
-
Quality improvement and implementation science in cancer care: Identifying areas of synergy and opportunities for further integration.
2019
-
A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.
2019
-
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).
2019
-
A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.
2019
-
A phase Ill trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
2019
-
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.
2019
-
A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).
2019
-
A video decision aid to improve acute myeloid leukemia patients' illness understanding: Results of a pilot trial.
2019
-
ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.
2019
-
ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
2019
-
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
2019
-
Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience.
2019
-
Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).
2019
-
Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).
2019
-
AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
2019
-
Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
2019
-
Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.
2019
-
CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).
2019
-
CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.
2019
-
Characterization of temporal relationships of comorbidities developed following cancer diagnoses in veterans.
2019
-
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
2019
-
CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
2019
-
Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
2019
-
Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC).
2019
-
Combination mTORC1/2 and BCL- XL
inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.
2019
-
Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
2019
-
Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.
2019
-
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
2019
-
Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.
2019
-
Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB).
2019
-
Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Operable Breast Cancer: A Randomized Controlled Trial (RCT).
2019
-
Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC).
2019
-
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
2019
-
Expression and prognostic relevance of calcium calmodulin-dependent protein kinase kinase 2 (CaMKK2) in chronic lymphocytic leukemia (CLL).
2019
-
External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
2019
-
Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).
2019
-
Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program.
2019
-
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
2019
-
Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.
2019
-
Immune checkpoint inhibitor response in tumors with LRP1B variants.
2019
-
Impact of a pilot patient navigator program on pediatric cancer outcomes in a low resource setting.
2019
-
Implementation of the VA Symptom Assessment Scale (VSAS): Five-year experience.
2019
-
Incidence of comorbidities on death certificate data in women with gynecological cancers.
2019
-
Inferior survival after microbiota injury: A multicenter alto-HCT study.
2019
-
Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
2019
-
MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.
2019
-
Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice patterns.
2019
-
Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.
2019
-
NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).
2019
-
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
2019
-
Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy.
2019
-
Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.
2019
-
PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
2019
-
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
2019
-
PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
2019
-
Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA
defects: A trial in progress.
2019
-
Patient preferences for maintenance PARP therapy in ovarian cancer treatment.
2019
-
Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
2019
-
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
2019
-
Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
2019
-
Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC >= 4
2019
-
Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).
2019
-
Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK plus non-small cell lung cancer (NSCLC).
2019
-
Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.
2019
-
Prognostic understanding in hematologic malignancies: A multicenter longitudinal study.
2019
-
Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (
Alliance A021202)
.
2019
-
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.
2019
-
Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).
2019
-
Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).
2019
-
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
2019
-
Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional analysis of 700 cases.
2019
-
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.
2019
-
Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).
2019
-
Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
2019
-
TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker.
2019
-
The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
2019
-
Therapy discontinuation processes in a gynecologic oncology population
2019
-
Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.
2019
-
Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).
2019
-
Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07).
2019
-
c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas.
2019
-
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.
2019
-
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.
2019
-
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
2019
-
The effect of adoptive transfer of ex vivo
activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.
2019
-
A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA
defects.
2019
-
A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.
2019
-
Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.
2019
-
Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.
2019
-
Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).
2019
-
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
2019
-
Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
2019
-
Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
2019
-
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
2019
-
Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.
2019
-
Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
2019
-
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
2019
-
Multi-institutional analysis of synchronous prostate and rectosigmoid cancers.
2019
-
Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).
2019
-
PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).
2019
-
PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
2019
-
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
2019
-
Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
2019
-
Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.
2019
-
Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
2019
-
Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).
2019
-
Sarcopenia in bladder cancer patients is an unmodifiable outcomes predictor.
2019
-
Sipuleucel-T to modify the B7-H3 immune checkpoint in men with castrate resistant prostate cancer.
2019
-
The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.
2019
-
The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).
2019
-
Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
2019
-
ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
2019
-
Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).
2019
-
Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
2019
-
Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).
2019
-
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
2019
-
Potentially avoidable acute care use among patients receiving oxaliplatin.
2019
-
Quantifying the evolution of tumor architecture using serial circulating tumor DNA.
2019
-
Validation of the NCI Colorectal Cancer Risk Assessment Tool for baseline advanced neoplasia in a veterans cohort.
2019
-
Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.
2019
-
Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL):A single-center retrospective analysis.
2019
-
Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: Preliminary results from multi-site study in the U.S.
2018
-
Palliative care physicians' beliefs toward hematology and the care of patients with hematologic diseases: Results of a nationwide survey.
2018
-
Quality of life and psychological distress in patients with acute myeloid leukemia (AML).
2018
-
The feasibility of an inpatient intervention to improve end-of-life care in gynecologic oncology patients.
2018
-
What the HEC? Physician variation and attainable compliance targets in antiemetic prophylaxis.
2018
-
Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?
2018
-
Feasibility of cancer clinical trial enrollment goals based on cancer incidence.
2018
-
National trends in end of life care for veterans with advanced cancer.
2018
-
Opioid-associated deaths in patients with cancer: A population study of the opioid epidemic over the past 10 years.
2018
-
The costs of breast cancer care: Patient-reported experiences and preferences for transparency.
2018
-
The quality of breast cancer quality measures.
2018
-
Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).
2018
-
A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.
2018
-
A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).
2018
-
A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.
2018
-
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
2018
-
A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.
2018
-
A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET
amplification (amp) detected in blood.
2018
-
A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.
2018
-
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
2018
-
A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
2018
-
A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).
2018
-
A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.
2018
-
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
2018
-
Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC).
2018
-
Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
2018
-
Assessment of activating estrogen receptor 1 (ESR1
) mutations in gynecologic malignancies.
2018
-
Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors.
2018
-
Barriers to palliative care (PC) utilization in hematopoietic stem cell transplantation (HCT).
2018
-
Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?
2018
-
Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).
2018
-
Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.
2018
-
Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.
2018
-
Chronic myeloid leukemia among veterans from 2006-2015: Trends in utilization of tyrosine kinase inhibitors.
2018
-
Comparison of cancer incidence to available oncology clinical trial slots.
2018
-
Comprehensive evaluation of place of death for patients with hematological malignancies, 1999-2015.
2018
-
Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.
2018
-
DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.
2018
-
Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).
2018
-
Development of a digital patient navigation application: Results from subject interviews.
2018
-
Durable clinical responses observed from non-Hodgkin lymphoma patients treated with autologous CAR-T cells targeting CD19.
2018
-
Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.
2018
-
Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).
2018
-
Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.
2018
-
Hospice use among Medicare fee-for-service (FFS) or managed-care organization (MCO) enrollees with leukemia and myeloma.
2018
-
Identifying chemotherapy-induced peripheral neuropathy (CIPN) and its treatment using claims data: A URCC NCORP and NIH Collaboratory study.
2018
-
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
2018
-
Immune profiling of BRCA-mutated breast cancers.
2018
-
Improved survival of small cell lung cancer in the veterans health administration from 2000-2010: Association with increasing utilization of PET staging.
2018
-
Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced ovarian cancer.
2018
-
KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.
2018
-
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).
2018
-
Meeting the needs of women at high risk for breast cancer: Facilitated group visits.
2018
-
Molecular testing during AML treatment for early prediction of clinical response.
2018
-
Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
2018
-
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab
-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).
2018
-
Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).
2018
-
Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.
2018
-
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
2018
-
Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A
alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2018
-
Patient(Pt)-reported toxicities by chemotherapy regimen for early breast cancer (BC) (LCCC1334/1440).
2018
-
Patient(Pt)-reported toxicities during breast cancer (BC) chemotherapy (CRx): Associations with pre-treatment (Tx) measures of quality of life (QOL) and Tx discontinuation.
2018
-
Patient-clinician communication about nutrition, weight, fitness, and fatigue in cancer care.
2018
-
Patterns of bone scan and pain response following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
2018
-
Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.
2018
-
Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
2018
-
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
2018
-
Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
2018
-
Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).
2018
-
Phase I study of muscadine grape extract in advanced malignancy.
2018
-
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
2018
-
Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.
2018
-
Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
2018
-
Physicians’ comfort levels with prescriptions for cancer comorbidities that they and other healthcare providers write.
2018
-
Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
2018
-
Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis.
2018
-
Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
2018
-
Psychological distress in myelodysplastic syndromes.
2018
-
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
2018
-
Quality of life and psychological distress in patients with acute myeloid leukemia (AML).
2018
-
Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.
2018
-
Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.
2018
-
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
2018
-
Restaging de novo metastatic breast cancer to refine prognostic estimates.
2018
-
SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.
2018
-
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
2018
-
Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.
2018
-
TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.
2018
-
Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, the Children’s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.
2018
-
The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).
2018
-
The effect of a lay health worker-led symptom assessment intervention for patients on patient-reported outcomes, healthcare use, and total costs.
2018
-
The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.
2018
-
The importance of body composition and physical function on overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy (PBCT).
2018
-
Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study.
2018
-
Topical sildenafil in the treatment of hand-foot syndrome and hand-foot skin reaction: A retrospective study.
2018
-
Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.
2018
-
Trends and disparities in place of death for cancer patients in the United States, 1999-2015.
2018
-
Using a geriatric oncology assessment to link with services in an underserved, community oncology population.
2018
-
Variability in Medicare utilization and payment among gynecologic oncologists.
2018
-
What factors drive the choice of a genetic test? A prospective study of the preferences of women with ovarian cancer.
2018
-
Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).
2018
-
Assessing key stakeholders' knowledge, needs, and preferences for cancer survivorship care plans.
2018
-
Cardiovascular disease-related chronic conditions among Veterans Affairs colorectal cancer survivors: A matched case-control analysis.
2018
-
Development of a digital patient navigation application: Preliminary results from patient interviews.
2018
-
Perceptions of unintentional weight loss among cancer survivors.
2018
-
Text messaging and activity tracker motivation program to increase physical activity in cancer survivors.
2018
-
A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).
2018
-
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
2018
-
A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2018
-
Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.
2018
-
Clinical utility of Foundation One tissue molecular profiling in men with metastatic prostate cancer.
2018
-
Consensus statement on circulating biomarkers for advanced prostate cancer.
2018
-
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).
2018
-
Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.
2018
-
Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.
2018
-
Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2 (CAPS2).
2018
-
Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications.
2018
-
Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.
2018
-
Patients perspectives on adjuvant therapy in renal cell carcinoma.
2018
-
Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
2018
-
Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.
2018
-
Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.
2018
-
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.
2018
-
S-TRAC trial: Sensitivity analyses of disease-free survival (DFS).
2018
-
Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.
2018
-
A precision medicine strategy to identify the FGFR pathway as a novel target in colorectal cancer liver metastasis.
2018
-
AGITG nabnec: A randomised phase II study of nab
-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.
2018
-
Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).
2018
-
BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.
2018
-
Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
2018
-
Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis.
2018
-
Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.
2018
-
Comparison of annotation services for the VA Precision Oncology Program.
2018
-
Four Conversations: A randomized control trial of an online, shared decision making curriculum among the metastatic breast cancer community.
2017
-
Integration and expansion of palliative care work force.
2017
-
Open notes: A qualitative study of oncology patients’ experiences reading their cancer care notes.
2017
-
Perceptions of prognosis and treatment risk in older patients with acute myeloid leukemia (AML).
2017
-
Use of hospice services among Medicare beneficiaries with acute and chronic leukemias.
2017
-
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
2017
-
A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
2017
-
A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.
2017
-
A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.
2017
-
A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.
2017
-
A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).
2017
-
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
2017
-
A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients.
2017
-
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
2017
-
A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.
2017
-
American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance).
2017
-
Antitumor efficacy of CDK 4/6 dual inhibitor, abemaciclib, in an esophageal adenocarcinoma model.
2017
-
Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.
2017
-
Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).
2017
-
Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.
2017
-
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
2017
-
Bridging the financial assistance gap: A pilot study of a patient-facing app to identify drug financial assistance programs.
2017
-
Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.
2017
-
Cost-effectiveness of ovarian cancer screening: An analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) from a U.S. health system perspective.
2017
-
Disrupting end-of-life cancer care delivery: Results from the engagment of patients with advanced cancer trial.
2017
-
Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).
2017
-
Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).
2017
-
Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.
2017
-
Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
2017
-
Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+
T cells in ovarian cancer.
2017
-
Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.
2017
-
Feasibility intervention to increase exercise outcome expectations among breast cancer survivors.
2017
-
First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
2017
-
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
2017
-
Impact of hearing and visual impairment in older adults with cancer.
2017
-
Impact of insurance status on treatment for stage 0-IV breast cancer.
2017
-
LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).
2017
-
Magnitude and duration of immune checkpoint up-regulation and changes in the immune microenvironment post chemo-radiation (CRT) in esophageal cancer.
2017
-
Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?
2017
-
Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.
2017
-
Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.
2017
-
Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.
2017
-
Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries.
2017
-
Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).
2017
-
Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.
2017
-
Paracrine wnt-β-catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma.
2017
-
Patient-reported distress in myelodysplastic syndromes and its relationship with clinical outcomes.
2017
-
Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.
2017
-
Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).
2017
-
Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
2017
-
Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.
2017
-
Primary (1 degrees) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).
2017
-
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
2017
-
RNA turbulence by tumor type: Overexpression of actionable mRNA signaling pathways by histology.
2017
-
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).
2017
-
Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.
2017
-
Risk tolerance and attitudes toward chemotherapy: Who chooses palliative treatment when cure is possible?
2017
-
Role of axillary node dissection after mastectomy with positive sentinel nodes.
2017
-
Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
2017
-
Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance).
2017
-
Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).
2017
-
Shared decision-making in ovarian cancer.
2017
-
Short- and long-term outcomes of early stage non-small cell lung cancer (NSCLC) surgery.
2017
-
Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).
2017
-
Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.
2017
-
Survivorship needs after head and neck cancer treatment.
2017
-
Temporal associations between prognostic indicators and overall survival after breast cancer.
2017
-
Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
2017
-
The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database.
2017
-
The impact of continuing medical education (CME) programs in metastatic castration-resistant prostate cancer (CRPC).
2017
-
Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P): Based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).
2017
-
Treatment through progression with ofranogene obadenovec (VB-111), an anti-cancer viral therapy, significantly attenuates tumor growth in recurrent GBM: Individual phase 2 patient data.
2017
-
Unusual disease characteristics of multiple myeloma in eastern North Carolina.
2017
-
Validation of the NCI colorectal cancer risk assessment tool in the CSP 380 veterans cohort.
2017
-
Harmonization of patient-reported outcomes into EHRs at four cancer hospital outpatient clinics for patient care and quality assessment.
2017
-
Investigating associations between health-related quality of life and endocrine therapy under-utilization in women with early-stage breast cancer.
2017
-
A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.
2017
-
Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.
2017
-
Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).
2017
-
Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4.
2017
-
Ruxolitinib in treatment of refractory hypereosinophilic syndrome.
2017
-
A nomogram for testosterone recovery following combined androgen deprivation therapy and radiation therapy for prostate cancer.
2017
-
Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients.
2017
-
OncotypeDx genomic scores independent of disease volume in men with favorable-risk prostate cancer.
2017
-
Caregiver preferences for increasing patient survival in advanced melanoma.
2017
-
A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.
2017
-
Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).
2017
-
Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.
2017
-
Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).
2017
-
Checkpoint expression pre and post chemoradiation in operable esophageal cancer.
2017
-
Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
2017
-
Interim FDG-PET imaging during neoadjuvant chemoradiotherapy for esophageal cancer: Correlation with pathologic response.
2017
-
Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance).
2017
-
Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
2017
-
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
2017
-
The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
2017
-
Healthcare utilization among cancer patients prior to hospice
2016
-
Inpatient integrated palliative and transplant care to improve family caregiver (FC) outcomes of patients hospitalized for hematopoietic stem cell transplantation (HCT).
2016
-
Is empathy associated with a derived sense of meaning among resident physicians working with patients nearing the end of life on a hematology-oncology ward?
2016
-
Patient-reported distress in adults with myelodysplastic syndromes (MDS).
2016
-
Randomized trial of inpatient palliative care in patients hospitalized for hematopoietic stem cell transplantation (HCT).
2016
-
Sleep quality among inpatients with acute myeloid leukemia.
2016
-
The elephant in the room: Facilitating conversations about advanced cancer between patients and their spouses.
2016
-
Who chooses palliative chemotherapy when a cure is possible? Results of a risk tolerance survey of laypersons.
2016
-
A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.
2016
-
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.
2016
-
A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).
2016
-
A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
2016
-
A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts).
2016
-
A preclinical study of a PI3K/mTOR dual inhibitor in the treatment of esophageal adenocarcinoma.
2016
-
A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
2016
-
Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.
2016
-
Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors.
2016
-
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
2016
-
Baseline cognitive function to predict survival in patients with glioblastoma.
2016
-
Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).
2016
-
Can lay health workers achieve the triple aim? Results from the Engagement of Patients with Advanced Cancer (EPAC) trial.
2016
-
Cancer patient experience with financial counseling among participants of an online registry.
2016
-
Chemotherapy and radiotherapy in early stage uterine papillary serous and clear-cell carcinoma: A National Cancer Data Base study.
2016
-
Circulating cancer associated macrophage-like cells in the detection of invasive breast cancer.
2016
-
Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).
2016
-
Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG).
2016
-
Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry.
2016
-
Defining the characteristics of medical oncology patients requiring inpatient hospital admission.
2016
-
Deletions in HSP110 T17
and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147.
2016
-
Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).
2016
-
Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.
2016
-
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.
2016
-
Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
2016
-
Feasibility and safety of cardiopulmonary exercise testing (CPET) in adults newly diagnosed with acute leukemia undergoing induction therapy.
2016
-
Functional profiling of a glioblastoma (GBM) patient-derived cell line (PDCL) panel to identify cell-intrinsic differential radiation response.
2016
-
Health plan selection and out-of-pocket costs for cancer patients in the health insurance exchange.
2016
-
Identification of novel EGFR
ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests.
2016
-
Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
2016
-
Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.
2016
-
Initiation and adherence with bone-targeting agents in US men with bone metastases from prostate cancer.
2016
-
NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
2016
-
NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.
2016
-
Next generation sequencing for DLBCL classification.
2016
-
NiCord single unit expanded umbilical cord blood transplantation: Results of phase I/II trials.
2016
-
Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
2016
-
Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.
2016
-
Optimal timing of lobectomy for clinical stage IA non-small cell lung cancer.
2016
-
Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.
2016
-
Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.
2016
-
Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.
2016
-
Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.
2016
-
Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3
-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study.
2016
-
Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).
2016
-
Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
2016
-
Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.
2016
-
Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
2016
-
Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).
2016
-
Pilot study of an online app to reduce cancer patients' financial burden.
2016
-
Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
2016
-
Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry.
2016
-
Randomized trial of an inpatient palliative care intervention in patients hospitalized for hematopoietic stem cell transplantation (HCT).
2016
-
Results of a survey of oncology nurses assessing practice patterns and adherence to antiemetic guidelines.
2016
-
Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study.
2016
-
Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).
2016
-
Shared decision-making tools for patients with hematologic malignancies.
2016
-
Surgery versus optimal medical management of early-stage small cell lung cancer.
2016
-
Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.
2016
-
Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors.
2016
-
T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.
2016
-
Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab
-P) in breast cancer.
2016
-
The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS).
2016
-
Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.
2016
-
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
2016
-
Association of high rates of practice-level inpatient-intensity with end-of-life outcomes, readmission rates, and weekend hospitalizations among Medicare patients with cancer
2016
-
Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.
2016
-
Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among breast cancer patients.
2016
-
Validation and quality assessment of the Kilimanjaro Cancer Registry.
2016
-
Effect of combined neoadjuvant chemoradiation on overall survival for patients with locally advanced rectal cancer.
2016
-
X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).
2016
-
Colorectal cancer survivorship statistics: A Veterans Affairs Central Cancer Registry analysis.
2016
-
A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints.
2016
-
Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.
2016
-
Application of active surveillance threshold to series of samples submitted for commercial testing.
2016
-
Associations between health-related quality of life and physical activity in bladder cancer survivors: A cross-sectional study.
2016
-
Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.
2016
-
Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL.
2016
-
Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
2016
-
Effect of diet on bladder cancer survivors.
2016
-
Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.
2016
-
NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.
2016
-
Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.
2016
-
Once-nightly (QD) dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464 in patients with CRPC.
2016
-
Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).
2016
-
Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry.
2016
-
Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry.
2016
-
Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC).
2016
-
Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.
2016
-
Your opinion counts: How do you treat atypical/suspicious cytology?
2016
-
Fatigue in long-term non-Hodgkin lymphoma survivors.
2015
-
Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML).
2015
-
Pruritus as an unmet palliative care need in cancer patients: A retrospective cohort study of a Duke patient-reported outcomes database.
2015
-
Severity of and contributors to distress in patients with acute myeloid leukemia (AML) receiving induction chemotherapy.
2015
-
Symptom burden and palliative care for patients with multiple myeloma: Cancer Experience Registry findings.
2015
-
Group visits for women at high risk for breast cancer: Facilitated education and support sessions.
2015
-
A discrete choice experiment to examine the preferences of patients with cancer and their willingness to pay for different types of health care appointments.
2015
-
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
2015
-
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)
2015
-
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
2015
-
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.
2015
-
Acute Myeloid Leukemia (AML) PatientsÂ’ Understanding of Prognosis and Treatment Goals: A Mixed-Methods Study.
2015
-
Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.
2015
-
Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.
2015
-
Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884).
2015
-
Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.
2015
-
Characteristics and survival of African American (AA) newly diagnosed multiple myeloma (NDMM) patients (Pts): A report from the Connect MM Registry.
2015
-
Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405
2015
-
Duke University Global Cancer Program: A multidisciplinary approach to partnerships in global cancer care.
2015
-
Early detection of breast cancer using a unique tumor specific antibody
2015
-
Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.
2015
-
Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study.
2015
-
Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy.
2015
-
Epidermal growth factor receptor (EGFR) testing among veterans diagnosed with lung cancer in the VA.
2015
-
Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.
2015
-
Fatigue in long-term non-Hodgkin lymphoma survivors
2015
-
Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)
2015
-
Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.
2015
-
Grip strength and timed get-up-and-go: Associations with symptoms among women taking adjuvant endocrine therapy.
2015
-
HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS
-wt advanced colorectal cancer (aCRC).
2015
-
HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).
2015
-
Health related quality of life (HRQOL) in older adults with cancer: The potential of a single-item screen
2015
-
Identification of glioblastoma patients who stand to benefit from PARP inhibitor therapy.
2015
-
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes
2015
-
Implementation of gene expression testing for breast cancer patients within the Veterans Health Administration.
2015
-
Machine-learning prediction of cancer survival: A prospective study examining the impact of combining clinical and genomic data.
2015
-
Mutational analysis of matched initial and recurrent TP53 WT primary GBM.
2015
-
NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.
2015
-
Nationwide utilization of cardiac imaging in patients undergoing cardiotoxic chemotherapy.
2015
-
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.
2015
-
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.
2015
-
Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry.
2015
-
Pan-caspase peptide inhibitor to induce primary chronic lymphocytic leukemia (CLL) cell death through a non-apoptotic and non-necroptotic mechanism.
2015
-
Patients' and physicians' risk-benefit trade-off preferences for metastatic colorectacl cancer treatments.
2015
-
Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).
2015
-
Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.
2015
-
Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
2015
-
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
2015
-
Phase II trial of dovitinib in recurrent glioblastoma.
2015
-
Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
2015
-
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
2015
-
Quality of life, depression, and end-of-life outcomes in hospitalized patients with advanced cancer
2015
-
Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere.
2015
-
Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
2015
-
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
2015
-
Risk factors for interval advanced colorectal neoplasia after screening colonoscopy.
2015
-
SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.
2015
-
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer (LARC): Final results of a phase Ib study.
2015
-
Secondary cancers in long-term survivors of primary glioblastoma.
2015
-
Self-reported sexual function measures administered to female cancer patients: A systematic review, 2008-2014.
2015
-
Survival benefit of tumor treating fields plus stereotactic radiosurgery for recurrent malignant gliomas.
2015
-
Symptom burden, quality of life, and distress in acute myeloid leukemia patients receiving induction chemotherapy: A prospective electronic patient-reported outcomes study.
2015
-
Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).
2015
-
Targeting the Wnt5a-β-catenin pathway in the melanoma microenvironment to augment checkpoint inhibitor immunotherapy.
2015
-
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).
2015
-
Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).
2015
-
Utilization of BRCA1/BRCA2
testing in Veterans Health Administration.
2015
-
Vesicular monoamine transporter protein expression in neuroblastoma: A report from the Children's Oncology Group.
2015
-
Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).
2015
-
Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience.
2015
-
Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.
2015
-
Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.
2015
-
High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).
2015
-
The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.
2015
-
A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F).
2015
-
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).
2015
-
Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies.
2015
-
Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
2015
-
Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).
2015
-
Role of microbiota and Toll-like receptors in progression of esophageal adenocarcinoma (EAC) in a rat reflux model.
2015
-
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
2015
-
Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).
2015
-
Use of mobile device technology to collect patient-reported symptoms during radiotherapy for head and neck cancer: A prospective feasibility study
2015
-
Obesity and guideline-concordant systemic therapy for locoregional breast cancer.
2014
-
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).
2014
-
A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).
2014
-
A multicenter observational study comparing physician-assessed febrile neutropenia (FN) risk and prediction-model severe neutropenia (SN) or FN risk in patients (pts) with nonmyeloid malignancies.
2014
-
A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
2014
-
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
2014
-
A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015.
2014
-
A pilot study evaluating the safety and impact of pretreatment with metformin on colorectal cancer stem cells (CCSC) in patients undergoing resection.
2014
-
A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).
2014
-
A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer
2014
-
A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.
2014
-
Absence of occult micrometastases in histologically negative lymph nodes among patients with distant recurrent endometrial cancer.
2014
-
Association between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients.
2014
-
Association between metformin (M) use and survival among non-small cell lung cancer (NSCLC) patients (pts).
2014
-
Association of adjuvant chemotherapy with improved survival after esophagectomy without induction therapy for node-positive adenocarinoma.
2014
-
Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).
2014
-
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.
2014
-
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (RV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
2014
-
Can we identify patients at risk for discordance in preferred and actual role in cancer treatment decision making?
2014
-
Change in palliative performance scale score as prediction of survival in patients with advanced cancer.
2014
-
Changes in androgen deprivation therapy overuse: Reimbursement response and characteristics of persistent overusers.
2014
-
Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).
2014
-
Clinical trial subjects compared to "real world" patients: Generalizability of renal cell carcinoma trials.
2014
-
Combinatorial TGF-β signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAFV600E
-PTEN-/- transgenic model of melanoma.
2014
-
Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry.
2014
-
Correlation between the international consensus definition of the cancer anorexia cachexia syndrome (CACS) and patient outcomes in advanced non-small cell lung cancer (NSCLC).
2014
-
Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal adenocarcinoma.
2014
-
Does cancer treatment-related financial distress worsen over time?
2014
-
Endometrial cancer outcomes in hypertensive women treated with beta-blocker.
2014
-
Enobosarm and lean body mass in patients with non-small cell lung cancer.
2014
-
Evaluation of an online, skill-building, group intervention for cancer patients and caregivers: Pillars4Life.
2014
-
Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study (CCSS).
2014
-
Exploring variations in multiple myeloma management through in-practice research.
2014
-
Feasibility and results of a randomized phase Ιb study of fractionated 90
Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.
2014
-
Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.
2014
-
Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer.
2014
-
Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.
2014
-
Geographic variation in high-risk uterine cancer histology and access to care.
2014
-
Identification and validation of actionable mutations in solid tumors.
2014
-
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
2014
-
Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.
2014
-
Impact of chemotherapy dose and schedule on progression and survival in metastatic breast cancer: A systematic review.
2014
-
Initial utilization of Oncotype DX in the Medicare population between 2005 and 2007.
2014
-
Is advanced imaging in early-stage breast cancer ever warranted? Exploring benchmarks for an ASCO Choosing Wisely quality measure.
2014
-
Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary
2014
-
Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.
2014
-
Mesothelin expression as a predictive biomarker of breast cancer outcomes.
2014
-
Metformin (M), diabetes (DM), and colorectal cancer (CRC) survival among U.S. veterans.
2014
-
Molecular profiling of bile duct and gallbladder cancer to identify different therapeutic options.
2014
-
Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF
fusion.
2014
-
Nodal stage of surgically resected non-small cell carcinoma of the lung and its effect on recurrence pattern and survival.
2014
-
Persistent pain following breast cancer surgery: A case-control study.
2014
-
Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.
2014
-
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
2014
-
Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).
2014
-
Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).
2014
-
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
2014
-
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.
2014
-
Prospective evaluation of KRAS, NRAS, BRAF
, and PI3KCA
mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).
2014
-
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
2014
-
Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG).
2014
-
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
2014
-
Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
2014
-
Relative influence of factors determining a woman’s preference for treatment options in ovarian cancer.
2014
-
Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.
2014
-
Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.
2014
-
Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial.
2014
-
Survival outcomes of patients (pts) who received filgrastim (fil) or pegfilgrastim (peg) in clinical trials.
2014
-
TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-
proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.
2014
-
Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab
)-paclitaxel for newly diagnosed breast cancer.
2014
-
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
2014
-
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.
2014
-
The underutilization of occupational and physical therapy for older adults with cancer.
2014
-
Validation of postinduction Curie scores in high-risk neuroblastoma.
2014
-
Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials.
2014
-
When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis.
2014
-
When should surgeons begin surveillance with CT scans after lobectomy for stage 1A non-small cell lung cancer?
2014
-
Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).
2014
-
Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.
2014
-
Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.
2014
-
Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.
2014
-
Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).
2014
-
Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM.
2014
-
Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: Data from PROCEED.
2014
-
Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.
2014
-
Open versus minimally invasive management of gastric GIST: An international multi-institutional analysis of short- and long-term outcomes.
2014
-
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
2014
-
Comparison of QOPI measure conformance between oncology fellows and attending physicians
2013
-
Identifying benchmarks for ASCO's "Choosing Wisely" measures that address low-value imaging in early-stage prostate and breast cancer
2013
-
Patient-oncologist cost communication, financial distress, and medication adherence.
2013
-
Tools to accurately identify veterans who undergo molecular diagnostic testing.
2013
-
(62)cuatsm and (62)cuptsm PET is a useful imaging tool for hypoxia and perfusion in lung cancer.
2013
-
25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303
2013
-
A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance)
2013
-
A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy
2013
-
A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258).
2013
-
A survey of clinical prediction took in colorectal and lung cancers and melanoma
2013
-
ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma
2013
-
An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).
2013
-
An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.
2013
-
Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.
2013
-
Application of the French prognostic score (FPS) to assess overall survival (OS) in a US-based cohort of patients (pts) treated with azacitidine (Aza).
2013
-
Are there racial differences in colorectal cancer care timeliness among users of the Veterans Affairs Healthcare System?
2013
-
Association between high-cost imaging and hospice use at the end of life of cancer patients.
2013
-
Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod
2013
-
Association of survival with chemotherapy intensity, myelosuppression, and supportive care in patients with advanced solid tumors
2013
-
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
2013
-
Autoimmune disorders in patients with B-cell chronic lymphocytic leukemia
2013
-
Baseline characteristics from two ongoing phase III trials for the prevention and treatment of muscle wasting in NSCLC.
2013
-
Cancer anorexia-cachexia syndrome in advanced lung cancer: An exploratory analysis of patient-reported outcomes data.
2013
-
Cardiorespiratory fitness and risk of cancer incidence and cause-specific mortality following a cancer diagnosis in men: The Cooper Center longitudinal study.
2013
-
Change in mammographic density with metformin use: A companion study to NCIC study MA.32.
2013
-
Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry
2013
-
Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487)
2013
-
Clinical impact of febrile neutropenia (FIN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer
2013
-
Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2)
2013
-
Colorectal cancer gene expression profiling using nanostring nCounter analysis
2013
-
Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101
2013
-
Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors
2013
-
Current status of the implementation of gene expression testing in breast cancer management in the United States
2013
-
Disparities in breast cancer presentation and treatment of older women, by insurance status.
2013
-
Does anatomic segmentectomy have better outcomes than wedge resections in stage I NSCLC patients treated by sub-lobar resection?
2013
-
Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.
2013
-
Early mortality (EM) for newly diagnosed multiple myeloma (NDMM) in the Connect MM US registry
2013
-
Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).
2013
-
Financial distress, communication, and cancer treatment decision making: Does cost matter?
2013
-
ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation
2013
-
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)
2013
-
Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).
2013
-
Incidence of febrile neutropenia and effectiveness of pegfilgrastim prophylaxis in patients with advanced-stage solid tumors receiving chemotherapy.
2013
-
Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy
2013
-
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer
2013
-
Oncologists' perceptions of rounding alongside palliative care physicians: Results of a post-intervention survey study.
2013
-
Patterns of care study of adult medulloblastoma.
2013
-
Patterns of second-line chemotherapy and its effect on survival in patients treated within the Veterans Health Administration (VHA)
2013
-
Phase I clinical trial of external hyperthermia and intravesical mitomycin C to treat BCG-refractory bladder cancer.
2013
-
Phase I/II dose-escalation study of VB-111, an antiangiogenic gene therapy, in patients with recurrent glioblastoma multiforme.
2013
-
Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.
2013
-
Predictors of care for early-stage breast cancer in Appalachia
2013
-
Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation
2013
-
Quality of life (QOL) and toxicity among patients in CALGB 80405
2013
-
Recurrence rates in patients with uterine papillary serous cancer with and without breast cancer.
2013
-
Resource use and costs in the last year of life among Medicare beneficiaries who died from prostate cancer versus with the disease between 2000 and 2007.
2013
-
SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML)
2013
-
Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC)
2013
-
Screening for depression in community-based radiation oncology settings: Results from RTOG 0841
2013
-
TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).
2013
-
The financial burden of cancer care: Do patients know what to expect?
2013
-
The impact of diabetes and obesity on endometrial cancer outcomes
2013
-
The influence of diabetes severity on guideline-concordant treatment for stage I-III breast cancer in the National Program of Cancer Registries (NPCR) patterns of care for breast and prostate cancer study (POCBP)
2013
-
Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance)
2013
-
Usability testing of the PRO-CTCAE measurement system in patients with cancer.
2013
-
Use of flow cytometry during induction chemotherapy to determine outcomes in acute myeloid leukemia
2013
-
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed
2013
-
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
2013
-
A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa)
2013
-
Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).
2013
-
Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?
2013
-
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor
2013
-
Outcomes, complications, and costs of care of Bosniak IIF, III, and IV cystic renal lesions/malignancies: Data from the largest multi-institutional study to date.
2013
-
Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy
2013
-
Relationship of oral glycine with radiation-induced HIF1-alpha and tumor growth delay in a prostate cancer xenograft
2013
-
The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).
2013
-
Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence.
2013
-
A molecular profile of colorectal cancer to guide prognosis and therapy after resection of primary or metastatic disease.
2013
-
Survival trends of 89,543 patients with metastatic colorectal cancer: A population-based analysis.
2013
-
TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC).
2013
-
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.
2013
-
Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.
2013
-
Perceptions regarding prostate cancer (CaP) treatment options: Results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS)
2013
-
Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.
2013
-
A fully automated capillary western system for absolute quantitation of endogenous PKC proteins: An approach to correlate protein quantity with function.
2012
-
A nanofluidic immunoassay system to develop proteomic responsive biomarkers in non-small cell lung cancer.
2012
-
Ad5 immunity after multiple safe, homologous immunizations against tumor-associated antigens with new recombinant Ad5 vector
2012
-
Use of a novel patient-specific model of glioma growth kinetics to elucidate underlying biology as measured by gene expression microarray.
2012
-
Does atypical ductal hyperplasia require 6 months of postoperative surveillance?
2012
-
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).
2012
-
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).
2012
-
A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.
2012
-
A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial
2012
-
A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol-Report on the good-risk patients
2012
-
Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial.
2012
-
African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center
2012
-
Assessment of cancer registries (CR) in low- and middle-income countries (LMCs)
2012
-
Beyond metastatic renal cell carcinoma (mRCC) clinical trials: Targeted therapy use and overall survival in community oncology clinics
2012
-
Biochemical survival and morbidity of high-intensity focused ultrasound (HIFU) as a primary monotherapy for low-risk localized prostate cancer: Outcomes from the @-registry following the ENLIGHT trial inclusion criteria
2012
-
CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
2012
-
Cellular responses to lactate in breast cancer
2012
-
Chemotherapy associated myelosuppression and disease-free and overall survival: A systematic review and evidence summary.
2012
-
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC)
2012
-
Connect MM: The multiple myeloma ( MM) disease registry-Incidence of second primary malignancies (SPM).
2012
-
Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer
2012
-
Current patterns of chemotherapy and supportive care for early-stage breast cancer (ESBC).
2012
-
Effect of the loss of the type III TGF beta receptor during tumor progression on tumor microenvironment: Preclinical development of TGF beta inhibition and TGF beta-related biomarkers to enhance immunotherapy efficacy.
2012
-
Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial
2012
-
External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.
2012
-
Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN)
2012
-
Impact of salvage therapy with APC8015F on the overall survival (OS) benefit achieved with sipuleucel-T in three phase III studies of metastatic castrate-resistant prostate cancer (mCRPC)
2012
-
Influence of comorbidity on guideline concordant care for breast cancer: Findings from the Center for Disease Control and Prevention National Program of Cancer Registry (NPCR) patterns of care study.
2012
-
Isolation of circulating tumor cells using a novel EMT-based capture method.
2012
-
Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
2012
-
MET and ALK in glioblastoma multiforme (GBM): Comparison of IHC and FISH
2012
-
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study
2012
-
Modulation of angiogenic biomarkers in patients receiving high-dose TRC105
2012
-
Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors
2012
-
Neoadjuvant chemoradiation for potentially resectable gastric cancer.
2012
-
Outcomes after treatment of resectable, node-negative esophageal cancer: A risk-adjusted analysis of the Surveillance, Epidemiology, and End Results registry
2012
-
Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.
2012
-
Patterns of care in elderly patients with squamous cell carcinoma of the head and neck: A SEER-Medicare analysis
2012
-
Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.
2012
-
Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).
2012
-
Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer
2012
-
Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results.
2012
-
Post-prostatectomy PSA slope (ProsVue) in Gleason score >= 7 disease
2012
-
Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor
2012
-
Prospective cohort study of chemotherapy-associated toxicity and supportive care in oncology practice.
2012
-
Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy
2012
-
REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB)
2012
-
Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.
2012
-
Retrospective analysis of the impact of age on overall survival in patients with non-small cell lung cancer.
2012
-
Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study
2012
-
Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme
2012
-
Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial
2012
-
The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).
2012
-
The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401)
2012
-
VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia
2012
-
Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial
2012
-
Whole genome sequencing to characterize luminal-type breast cancer
2012
-
Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer
2012
-
Comparative effectiveness of intensity modulated radiation therapy (IMRT), proton therapy (PT), and conformal radiation therapy (CRT) in the treatment of localized prostate cancer.
2012
-
Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database
2012
-
Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2012
-
The effect of acute and chronic exposure to acetaldehyde-a mutagenic metabolite of dietary ethanol-on prostate cancer cells: A potential source of race disparity disfavoring black men.
2012
-
Value of prostate MRI in determining appropriate candidates for active surveillance.
2012
-
A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803.
2012
-
A phase I/II study of capecitabine (Cape), oxaliplatin (Ox), panitumumab (Pmab), and external beam radiation therapy (RT) for patients with esophagogastric carcinoma (EC).
2012
-
Patterns of failure following trimodality therapy for locally advanced esophageal cancer (EC).
2012
-
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
2012
-
The effect of vascular reconstruction on early postoperative outcomes after pancreaticoduodenectomy: An analysis of the American College of Surgeons National Surgical Quality Improvement Program database.
2012
-
Acceptability of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women with metastatic breast cancer (MBC)
2012
-
An international study of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites.
2012
-
Association between baseline physical function and comorbidity status with patient-reported quality of life after prostate cancer treatments: Combined analysis of two prospective cohort studies
2012
-
Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT.
2012
-
Evaluation of proteomic profiles of normal mucosa, Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC) obtained from humans and the Levrat's rat model of BE/EAC
2012
-
Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer
2012
-
Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer.
2012
-
Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
2012
-
The effect of tumor subtype on survival and the graded prognostic assessment (GPA) for patients with breast cancer and brain metastases.
2011
-
A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
2011
-
A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE).
2011
-
A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC).
2011
-
A survey of suspected familial breast cancer in Iraqi Kurdish women.
2011
-
Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.
2011
-
Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis.
2011
-
Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL.
2011
-
Assessment of clinical trials in oncology: An evaluation of 40,696 trials on ClinicalTrials.gov.
2011
-
Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer.
2011
-
Cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia (ALL).
2011
-
Different risk factors for mortality in younger and older women after breast-conserving surgery.
2011
-
Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries.
2011
-
Impact of traditional cardiovascular disease risk factors on long-term cardiovascular outcome in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
2011
-
Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.
2011
-
Outcomes in phase II trials of metastatic breast cancer: Where is the bar?
2011
-
Pharmaceutical involvement in phase II breast cancer clinical trials.
2011
-
Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: A survey of the American Academy of Family Physicians (AAFP).
2011
-
Presenting features of colorectal cancerin the Sulaimaniya province of Iraqi Kurdistan.
2011
-
Prevalence and impact of correlative science in breast cancer phase II trials.
2011
-
Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031.
2011
-
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).
2011
-
Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer.
2011
-
Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer (BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
2011
-
Safety and efficacy of single-agent adjuvant trastzumab in older women with breast cancer.
2011
-
Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
2011
-
Survivorship care plans for colorectal cancer survivors: What do primary care providers want and need?
2011
-
The role of biologic therapy in phase II breast cancer clinical trials.
2011
-
Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC)
2011
-
Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA.
2011
-
Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer.
2011
-
Development of an assay to predict oxaliplatin sensitivity from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissues.
2011
-
Resected pancreatic neuroendocrine tumors: Patterns of failure and disease-related outcomes with or without radiotherapy.
2011
-
Use of gene expression profiling to determine prognosis and therapeutic targets for patients with appendiceal carcinoma.
2011
-
ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.
2010
-
A clinico-genomic model of performance status in acute myeloid leukemia.
2010
-
A graded prognostic assessment (GPA) for women with breast cancer and brain metastases.
2010
-
A randomized phase II study of a novel antigen-presenting cell-targeted hCG-β vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer.
2010
-
A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer.
2010
-
A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.
2010
-
Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study.
2010
-
Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study.
2010
-
Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions
2010
-
Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101).
2010
-
Development of the patient-reported version of the common terminology criteria for adverse events (PRO-CTCAE).
2010
-
Does the revised TNM staging system for lung cancer better estimate actuarial rates of local/regional recurrence after surgery?
2010
-
Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells.
2010
-
Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S).
2010
-
Factors influencing use of genetic tests in clinical practice among U.S. oncologists.
2010
-
Gastrointestinal malignancies as a subsequent malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
2010
-
Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.
2010
-
Hypofractionated radiotherapy for oligometastatic non-small cell lung carcinoma.
2010
-
Implementing genomically-guided trials in non-small cell lung carcinoma (NSCLC).
2010
-
Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.
2010
-
Oral and extraoral plasmablastic lymphoma: Similarities and differences in clinicopathological characteristics.
2010
-
Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).
2010
-
Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).
2010
-
Pilot study of external hyperthermia and intravesical mitomycin-C to treat recurrent biadder cancer after failed standard therapy
2010
-
Primary CNS lymphoma in HIV-positive and -negative patients: Comparison of clinical characteristics, outcome, and prognostic factors.
2010
-
Refinement of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) via cognitive interviewing.
2010
-
Role of the type III TGF-b receptor in mediating immunosuppression during breast cancer progression.
2010
-
Routine versus clinically indicated post-treatment surveillance in head and neck cancer.
2010
-
Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine.
2010
-
Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).
2010
-
Use of gene expression signatures to predict in vivo sensitivity of human metastatic colorectal cancer to chemotherapy and to identify novel drug combinations.
2010
-
Use of health-related quality of life and clinical data as prognostic tools for survival prediction in a subgroup of metastatic cancer patients.
2010
-
Use of novel radiosensitizers and radiation-specific miRNAs to modulate radiation response in non-small cell lung adenocarcinoma (NSCLC).
2010
-
Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.
2010
-
Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
2010
-
Volumetric analysis of advanced thymic malignancies.
2010
-
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206
2009
-
Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)
2009
-
First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)
2009
-
A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma
2009
-
A prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma
2009
-
A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML)
2009
-
A survey of US and Canadian oncologists' attitudes toward the cost, cost-effectiveness (CE), and reimbursement of cancer drugs
2009
-
Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy
2009
-
Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors
2009
-
Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)
2009
-
Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results
2009
-
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206
2009
-
Can primary recurrences in surgical stage I-II uterine papillary serous carcinoma (UPSC) patients be salvaged?
2009
-
Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)
2009
-
Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801
2009
-
Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry
2009
-
Correlation of body mass index with toxicity and survival in locoregionally advanced head and neck cancer patients treated with induction chemotherapy and concurrent chemoradiotherapy
2009
-
Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial
2009
-
Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086)
2009
-
Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens
2009
-
Dual inhibition of alpha(V) integrins and Src kinase activity in colon cancer cells
2009
-
Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM
2009
-
Effect of treatment of patients with early-stage uterine carcinosarcoma
2009
-
Electronic patient-reported data capture as the foundation of a learning health care system
2009
-
Epidermal growth factor receptor variant III (EGFRvIII) vaccine ( CDX-110) in GBM
2009
-
Factors associated with chemotherapy receipt and intensity for stage IV colorectal cancer (CRC): A multihealth system, population-based study
2009
-
Impact of a psychosocial intervention on performance status and coping
2009
-
Improved outcomes in advanced stage uterine carcinosarcoma (mixed mullerian tumor [MMT])
2009
-
Integration of mRNA and microRNA profiles as prognostic and predictive markers in lung adenocarcinoma
2009
-
KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803
2009
-
Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood
2009
-
Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC)
2009
-
Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study
2009
-
Novel organic arsenic molecule darinaparsin: Development of IV and oral forms
2009
-
Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma
2009
-
Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas
2009
-
Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas
2009
-
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581
2009
-
Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab
2009
-
Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)
2009
-
Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL)
2009
-
Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM)
2009
-
The relationship between adherence to adjuvant hormonal therapy and survival among low-income, insured women with primary breast cancer
2009
-
Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s)
2009
-
What price for a year of life? A survey of US and Canadian oncologists
2009
-
A comparison of patient-reported outcomes (PROs) in National Cancer Institute-sponsored cancer treatment trials conducted during two time periods: 1999-2003 and 2003-2008
2009
-
Is patient self-reporting more accurate than clinician reporting of symptoms for predicting survival in patients with cancer? Meta-analysis of 30 closed EORTC randomized controlled trials
2009
-
Relationships among health-related quality of life indicators in cancer patients: A pooled study of baseline EORTC QLQ-C30 data from 6,739 patients
2009
-
Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial
2009
-
A genomic approach to define important and targetable molecular pathways in brain metastasis arising from solid tumors
2008
-
A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity
2008
-
A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer
2008
-
A phase I/II study of systemic ADH-1 in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma
2008
-
A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
2008
-
Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy
2008
-
E/Tablets to collect research-quality, patient-reported data
2008
-
Factors influencing outcome after pulmonary resection for colorectal cancer (CRC) metastases in the current era
2008
-
Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples
2008
-
Health-related quality of life (HR-QOL) and chronic health conditions (CHC) in survivors of childhood acute myelogenous leukemia (AML)
2008
-
Improved outcomes in patients with lymph node-only stage IV disease in clear cell sarcoma: Results from a large single-institution experience and SEER database analysis
2008
-
Integration of clinico-pathologic variables, mRNA, and microRNA profiles represents an optimal strategy to predict sensitivity to chemotherapeutic agents in breast cancer
2008
-
Local/regional recurrence following surgery for early-stage lung cancer: A 10-year experience with 975 patients
2008
-
Mortality burden of melanoma: Metastatic site-specific and temporal trends
2008
-
Neoadjuvant carboplatin and weekly paclitaxel for stage Ib-IIIa non-small cell lung cancer (NSCLC): A Brown University Oncology Group (BrUOG) phase II study
2008
-
Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy
2008
-
Prevalence of late morbidity in survivors of Hodgkin’s lymphoma (HL) treated during adulthood
2008
-
Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood
2008
-
Pulmonary marginal zone lymphoma: A single center experience and review of the SEER database
2008
-
Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer
2008
-
Survey of long-term follow-up programs in the United States for adult survivors of childhood brain tumors
2008
-
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
2008
-
The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer
2008
-
Use of physical performance measures to predict future disability and mortality in older cancer patients: The Health Aging and Body Composition Study (Health ABC)
2008
-
Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines
2008
-
A genomic approach to identify mechanisms associated with chemotherapy resistance
2007
-
A genomic signature of chemotherapeutic multidrug resistance provides a rational approach to identify patients for targeted therapy in advanced solid tumors
2007
-
A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC)
2007
-
A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)
2007
-
A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors
2007
-
A pilot study of myeloablative (MA) autologous stem Cell (Auto SCT) followed by reduced intensity (RI) allogeneic transplantation (AlloSCT) in children with relapsed/refractory(R/R) Hodgkin's disease (HD)
2007
-
Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML)
2007
-
Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)
2007
-
Antigen presenting cell (APC)-targeted hCG beta vaccine for cancer therapy
2007
-
Autologous transplantation for relapsed non-Hodgkin lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: A single center experience
2007
-
CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer
2007
-
Changes on endorectal MRI during neoadjuvant hormonal therapy for prostate cancer and biochemical outcome in men managed using radiation therapy: A prospective phase II Cancer and Leukemia Group B study
2007
-
Choice of adjuvant and first-line metastatic chemotherapy (CT) for colorectal cancer (CRC) treated in the Carolinas
2007
-
Clinical predictors of larynx preservation (LP) after multiagent concurrent chemoradiotherapy (MCCRT)
2007
-
Comorbidity, age and stage at diagnosis in colorectal cancer (CRC)
2007
-
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11)
2007
-
E-tablets to collect research-quality patient-reported data
2007
-
Gene expression patterns of oncogenic signaling pathways provide a novel approach to targeted therapeutics in advanced non-small cell lung cancer (NSCLC)
2007
-
Immune signatures hold prognostic import across solids tumors
2007
-
Impact of flaxseed supplementation and dietary fat restriction on prostate cancer proliferation and other biomarkers: Results of a Phase II randomized controlled trial (RCT) using a presurgical model
2007
-
Improved long-term survival in patients with intermediate thickness primary melanoma managed by sentinel node biopsy
2007
-
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants
2007
-
Molecular signature of esophageal adenocarcinoma derived from microarray analysis of paraffin-embedded specimens predicts systemic recurrence following resection
2007
-
Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status
2007
-
Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent
2007
-
Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC)
2007
-
Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
2007
-
Phase I trial of VNP40101M in children with recurrent brain tumors-A Pediatric Brain Tumor Consortium (PBTC) study
2007
-
Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM)
2007
-
Phase II trial of Gliadel plus O-6-benzylguanic (O-6-BG) for patients with recurrent glioblastoma multiforme
2007
-
Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas
2007
-
Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma
2007
-
Pilot study of dronabinol for adult patients with primary malignant gliomas
2007
-
Predictive model for mediastinal lymph node status at the time of mediastinoscopy
2007
-
Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
2007
-
Prevalence of osteoporosis in glioma patients on enzyme inducing anticonvulsants (EIAC) and/or glucocorticoids
2007
-
Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients
2007
-
Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study
2007
-
Temozolomide as a vaccine adjuvant in GBM
2007
-
The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer
2007
-
The effects of paclitaxel (PTX) and 2-methoxyestradiol (2-ME2) on tumor oxygenation and HIF-1 alpha in breast cancer
2007
-
The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803
2007
-
Tinzaparin prophylaxis in brain tumor patients
2007
-
Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation
2007
-
Understanding patient expectations in early-phase clinical trials
2007
-
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced non- small cell lung cancer (NSCLC)
2007
-
A comparison of combination docetaxel/carboplatin versus sequential docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
2006
-
A genomic strategy to combinatorial therapeutics in solid tumors.
2006
-
A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC).
2006
-
A lung cancer genomic risk prediction model derived from paraffin-embedded tissue.
2006
-
A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer.
2006
-
A novel role of DNA fragmentation factor as a tumor suppressor through maintaining genomic stability.
2006
-
A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.
2006
-
A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206.
2006
-
A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma - Final results.
2006
-
Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.
2006
-
An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).
2006
-
An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.
2006
-
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.
2006
-
CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).
2006
-
Differential canonical pathways derived from microarrays using RNA from paraffin-embedded non-small cell lung cancer tissue.
2006
-
Does positron emission tomography (PET) improve our ability to detect residual neck node (NN) disease in patients with squamous cell head and neck cancer (SCHNC) after definitive chemoradiotherapy?
2006
-
Ex vivo activation and expansion of gamma delta T cells for immunotherapy of glioblastorna.
2006
-
High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin - A CALGB 59804 correlative study.
2006
-
Lessons learned from two decades of sentinel node biopsies for melanoma.
2006
-
Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782.
2006
-
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer.
2006
-
Oral mucositis (OM) related morbidity and resource utilization in a prospective study of head and neck cancer (HNC) patients.
2006
-
Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102.
2006
-
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104.
2006
-
Phase II trial of Gliadel plus 0(6)-benzylguanine (0(6) -BG) for patients with recurrent glioblastoma multiforme.
2006
-
Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas.
2006
-
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results.
2006
-
Prognostic significance of children with cutaneous melanoma: Implications for treatment.
2006
-
Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry.
2006
-
Relationship between numeracy and breast cancer patients' estimates of adjuvant treatment benefit.
2006
-
Role of amifostine as a cytoprotectant in children >= 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy.
2006
-
Study participants' perceptions of the process and impact of receiving results of N9831.
2006
-
Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781.
2006
-
The relationship between older cancer survivors' reports of depression, anxiety and pain to health providers' findings and mortality.
2006
-
Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
2006
-
Tumor-specific peptide vaccination in newly-diagnosed patients with GBM.
2006
-
Measurement of quality of care for adjuvant chemotherapy of colorectal cancer.
2006
-
A phase 1 dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma
2005
-
A phase I trial of gefitinib (ZD1 839) plus rapamycin for patients with recurrent malignant glioma.
2005
-
A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104.
2005
-
A phase II study of estramustine (E), docetaxel (D) and exisulind in hormonerefractory prostate cancer (HRPC): Initial results of CALGB 90004.
2005
-
A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results.
2005
-
Characterization of the insulin-like growth factor pathway in endometrial cancers.
2005
-
Correlation of clinical outcome with natural killer (NK) response to an anti-cancer, dendritic cell-based vaccine.
2005
-
Criterion validity of Medicare chemotherapy claims in breast and lung cancer patients.
2005
-
Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results
2005
-
Excellent event-free survival (EFS) in newly diagnosed patients with supratentorial primitive neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue.
2005
-
Expression analysis of genes involved in ovarian cancer metastasis.
2005
-
Expression of phosphorylated epidermal growth factor receptor (p-EGFR) in early stage non-small cell lung cancer: its relationship with overexpression of EGFR and cyclooxygenase-2 (COX-2), and survival
2005
-
Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.
2005
-
Gene expression profiles that predict response to platinum and identify patterns of pathway deregulation in advanced ovarian cancer.
2005
-
Gene expression signatures for prognosis in NSCLC, coupled with signatures of oncogenic pathway deregulation, provide a novel approach for selection of molecular targets.
2005
-
Hedgehog signaling correlates with hepatocellular carcinoma progression.
2005
-
High dose chemotherapy with peripheral blood stem cell (PBSC) rescue in metastatic Ewing's sarcoma at diagnosis.
2005
-
High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial.
2005
-
High-risk osteosarcoma (OS): Preliminary results of the ISG-SSG II protocol.
2005
-
Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803.
2005
-
Monitoring tumor markers in serial sera predicts disease failure in lung cancer patients following surgery.
2005
-
Patterns of care among breast cancer patients with financial need: Information from a Medicaid-claims and tumor registry linked database.
2005
-
Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103.
2005
-
Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy.
2005
-
Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): Results of CALGB 39803.
2005
-
Results of Project LEAD (Leading the Way in Exercise and Diet) - A trial testing an intervention of telephone-counseling and mailed materials in improving physical functioning among older breast and prostate cancer survivors
2005
-
Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors
2005
-
The impact of age on clinical outcomes in men with hormone refractory prostate cancer
2005
-
The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803.
2005
-
Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial.
2005
-
A phase 2 trial of high-dose allovectin-7 in patients with advanced metastatic melanoma.
2004
-
A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients.
2004
-
A phase I/II study of preoperative oxaliplatin (0), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901.
2004
-
A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008.
2004
-
A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.
2004
-
A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904).
2004
-
A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials
2004
-
Effect of zoledronic acid on clinically meaningful changes in pain associated with metastatic prostate cancer.
2004
-
Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782.
2004
-
Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial.
2004
-
Erythropoietin (EPO) has no direct effect on tumor growth or angiogenesis in animal models.
2004
-
Health status, medical care, preventive screening, and risk behaviors in adult survivors of cancer diagnosed during adolescence: A report from the Childhood Cancer Survivor Study (CCSS).
2004
-
High degree of correlation between in vivo tumor oxygenation measurements and carbonic anhydrase IX tissue staining in operable human breast cancer.
2004
-
Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial
2004
-
Intraperitoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma
2004
-
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).
2004
-
Is the second primary malignancy an important competing cause of death in patients (pts) with squamous cell head and neck cancer (SCHNC)?
2004
-
New drug delivery approach for the treatment of prostate cancer (preclinical results and phase I study results).
2004
-
Pediatric melanoma: Risk factor and survival analysis of the SEER Cancer Registry database.
2004
-
Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma
2004
-
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer: Toxicity and outcome results.
2004
-
Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies.
2004
-
Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.
2004
-
Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer.
2004
-
Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma.
2004
-
Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.
2004
-
Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.
2004
-
Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581).
2004
-
Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated an Cancer and Leukemia Group B (CALGB) 9480.
2004
-
RARbeta P2 promoter methylation: Potential biomarker for use with breast Random Periareolar Fine Needle Aspiration in breast cancer risk assessment.
2004
-
Regulatory and effector T cell subsets and dendritic cells in breast cancer.
2004
-
Safety profile of therapeutic pox virus-based vaccines for cancer.
2004
-
Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480.
2004
-
Sentinel node staging of resectable colon cancer: Results of CALGB 80001.
2004
-
The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): A pooled analysis of CALGB studies.
2004
-
The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: Two year follow-up of a prospective randomized trial.
2004
-
Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583.
2004
-
Utility of end consolidation bone marrow aspirates in childhood acute lymphoblastic leukemia [ALL]: A Pediatric Oncology Group study [POG].
2004
-
Fulfillment of the uncertainty principle in cancer clinical trials.
2004
-
Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days
2004